metformin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 387.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.64 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 28, 2006 EMA CHEPLAPHARM Arzneimittel GmbH
March 3, 1995 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 13166.00 9.82 5619 309490 27736 50262279
Acute kidney injury 3422.68 9.82 5521 309588 222537 50067478
Hypoglycaemia 3047.24 9.82 2584 312525 50997 50239018
Metabolic acidosis 2105.76 9.82 1823 313286 37002 50253013
Diabetic ketoacidosis 2031.14 9.82 1309 313800 16563 50273452
Blood glucose increased 1858.28 9.82 2255 312854 69069 50220946
Glycosylated haemoglobin increased 962.95 9.82 676 314433 9930 50280085
Ketoacidosis 956.64 9.82 473 314636 3422 50286593
Diabetes mellitus inadequate control 932.38 9.82 722 314387 12423 50277592
Hyperkalaemia 865.90 9.82 1270 313839 46819 50243196
Euglycaemic diabetic ketoacidosis 736.19 9.82 357 314752 2462 50287553
Hyperglycaemia 734.23 9.82 1015 314094 35390 50254625
Systemic lupus erythematosus 666.72 9.82 56 315053 140566 50149449
Pemphigus 591.90 9.82 40 315069 120126 50169889
Hypoglycaemic coma 524.93 9.82 267 314842 2066 50287949
Glossodynia 516.26 9.82 58 315051 115511 50174504
Drug ineffective 515.98 9.82 3000 312109 816333 49473682
Hand deformity 488.65 9.82 35 315074 100164 50189851
Synovitis 484.40 9.82 92 315017 123773 50166242
Drug intolerance 450.92 9.82 420 314689 218684 50071331
Shock 440.87 9.82 592 314517 20058 50269957
Contraindicated product administered 433.99 9.82 192 314917 148766 50141249
Blood glucose decreased 414.89 9.82 539 314570 17672 50272343
Pancreatitis 401.96 9.82 847 314262 41767 50248248
Pancreatitis acute 401.40 9.82 610 314499 23202 50266813
Arthropathy 400.06 9.82 244 314865 157662 50132353
Treatment failure 395.32 9.82 181 314928 137456 50152559
Anuria 372.54 9.82 403 314706 10841 50279174
Infusion related reaction 363.12 9.82 313 314796 169244 50120771
Pericarditis 360.32 9.82 36 315073 78653 50211362
Renal failure 353.01 9.82 1457 313652 105176 50184839
Diarrhoea 338.26 9.82 5336 309773 583140 49706875
Hyperlactacidaemia 336.44 9.82 202 314907 2231 50287784
Diabetic metabolic decompensation 334.79 9.82 170 314939 1310 50288705
Joint swelling 330.18 9.82 642 314467 244644 50045371
Blood glucose abnormal 326.87 9.82 296 314813 6376 50283639
Pemphigoid 315.11 9.82 275 314834 5632 50284383
Alopecia 309.74 9.82 665 314444 244382 50045633
Swelling 293.23 9.82 500 314609 200372 50089643
Rheumatoid arthritis 293.10 9.82 507 314602 202043 50087972
Wound 291.69 9.82 147 314962 105647 50184368
Vomiting 286.95 9.82 4237 310872 456521 49833494
Rheumatoid factor positive 284.97 9.82 5 315104 49854 50240161
Duodenal ulcer perforation 263.09 9.82 4 315105 45607 50244408
Rash 262.01 9.82 1624 313485 435847 49854168
Dehydration 259.16 9.82 1731 313378 150718 50139297
Therapeutic product effect decreased 245.70 9.82 291 314818 135759 50154256
Haemodialysis 244.86 9.82 281 314828 8081 50281934
Drug level increased 240.29 9.82 431 314678 18837 50271178
Hypothermia 239.11 9.82 333 314776 11683 50278332
Hypersensitivity 236.73 9.82 628 314481 214533 50075482
Discomfort 228.35 9.82 203 314906 108177 50181838
Pain 215.09 9.82 2439 312670 576464 49713551
Infection 209.63 9.82 480 314629 172474 50117541
Helicobacter infection 207.28 9.82 31 315078 49671 50240344
Toxicity to various agents 201.62 9.82 2116 312993 210383 50079632
Off label use 197.45 9.82 1946 313163 472480 49817535
Muscle injury 192.95 9.82 9 315100 37102 50252913
Vitamin B12 deficiency 190.39 9.82 173 314936 3743 50286272
Product use issue 185.87 9.82 409 314700 149066 50140949
Blood lactic acid increased 182.95 9.82 199 314910 5386 50284629
Continuous haemodiafiltration 182.79 9.82 99 315010 883 50289132
Folliculitis 182.03 9.82 17 315092 39208 50250807
Pancreatic carcinoma 178.89 9.82 207 314902 6007 50284008
Abdominal discomfort 178.68 9.82 788 314321 230853 50059162
Rhabdomyolysis 173.00 9.82 586 314523 38441 50251574
Musculoskeletal stiffness 172.01 9.82 337 314772 128144 50161871
Drug interaction 168.73 9.82 1943 313166 197678 50092337
Sleep disorder due to general medical condition, insomnia type 165.55 9.82 7 315102 31440 50258575
Irritable bowel syndrome 161.61 9.82 59 315050 51382 50238633
Weight decreased 160.80 9.82 2093 313016 219152 50070863
Blood glucose fluctuation 155.89 9.82 159 314950 3987 50286028
Pyrexia 154.85 9.82 1567 313542 378636 49911379
Diabetes mellitus 153.53 9.82 659 314450 48374 50241641
Impaired healing 141.87 9.82 135 314974 69651 50220364
Stomatitis 137.21 9.82 264 314845 101080 50188935
Febrile neutropenia 137.01 9.82 249 314860 97418 50192597
Arthralgia 134.35 9.82 1924 313185 436778 49853237
Maternal exposure during pregnancy 132.74 9.82 528 314581 159250 50130765
Drug hypersensitivity 125.13 9.82 982 314127 250028 50039987
Sinusitis 123.23 9.82 594 314515 169964 50120051
Neurologic neglect syndrome 118.71 9.82 87 315022 1371 50288644
Psoriasis 118.58 9.82 786 314323 68214 50221801
Hypomagnesaemia 117.34 9.82 364 314745 22792 50267223
Intentional overdose 116.63 9.82 727 314382 61777 50228238
Carotid artery thrombosis 114.32 9.82 86 315023 1413 50288602
Hepatic enzyme increased 112.81 9.82 456 314653 136924 50153091
Fatigue 108.03 9.82 3473 311636 704128 49585887
Acidosis 107.89 9.82 213 314896 10014 50280001
Nausea 106.55 9.82 5387 309722 700011 49590004
Tachypnoea 105.49 9.82 261 314848 14316 50275699
Overdose 104.94 9.82 1015 314094 98712 50191303
Blood bicarbonate decreased 103.36 9.82 105 315004 2620 50287395
Neutropenia 103.02 9.82 522 314587 147443 50142572
Renal impairment 102.98 9.82 815 314294 74846 50215169
Blood creatinine increased 102.91 9.82 819 314290 75341 50214674
Ill-defined disorder 100.63 9.82 115 314994 54539 50235476
Completed suicide 100.46 9.82 1259 313850 130630 50159385
Personality disorder 100.05 9.82 129 314980 4195 50285820
C-reactive protein abnormal 96.02 9.82 27 315082 27782 50262233
Adjustment disorder 95.82 9.82 88 315021 1931 50288084
Hemiplegia 95.74 9.82 168 314941 7213 50282802
Ketosis 95.33 9.82 52 315057 471 50289544
Contusion 91.69 9.82 373 314736 111810 50178205
Myocardial infarction 88.26 9.82 895 314214 88132 50201883
Injection site nodule 87.24 9.82 106 315003 3242 50286773
Polyuria 85.86 9.82 157 314952 6964 50283051
Product residue present 84.11 9.82 109 315000 3563 50286452
MELAS syndrome 81.28 9.82 30 315079 91 50289924
Postprandial hypoglycaemia 77.38 9.82 25 315084 43 50289972
Vasoplegia syndrome 76.39 9.82 60 315049 1054 50288961
Urine ketone body present 76.19 9.82 83 315026 2250 50287765
Ketonuria 75.32 9.82 43 315066 429 50289586
Blister 74.93 9.82 276 314833 85142 50204873
Hip arthroplasty 74.24 9.82 49 315060 30380 50259635
Acetonaemia 73.77 9.82 26 315083 66 50289949
Diabetic neuropathy 73.66 9.82 101 315008 3490 50286525
Hepatic steatosis 71.95 9.82 322 314787 24062 50265953
Rheumatic fever 71.53 9.82 10 315099 16857 50273158
Angioedema 69.50 9.82 437 314672 37239 50252776
Hypotension 69.22 9.82 1938 313171 233531 50056484
Hypoglycaemic encephalopathy 68.97 9.82 34 315075 244 50289771
Microalbuminuria 67.63 9.82 36 315073 309 50289706
Anion gap increased 66.64 9.82 63 315046 1436 50288579
Cardiac arrest 64.28 9.82 800 314309 82851 50207164
Coma acidotic 64.12 9.82 25 315084 92 50289923
Anaemia vitamin B12 deficiency 64.07 9.82 35 315074 318 50289697
Death 63.73 9.82 1541 313568 323838 49966177
Peripheral swelling 61.47 9.82 907 314202 205029 50084986
Diabetic retinopathy 60.91 9.82 72 315037 2138 50287877
Circulatory collapse 60.44 9.82 266 314843 19734 50270281
Nasopharyngitis 59.93 9.82 843 314266 192084 50097931
Therapeutic product effect incomplete 59.67 9.82 330 314779 91185 50198830
Cytomegalovirus infection 59.18 9.82 19 315090 17943 50272072
Bradycardia 58.34 9.82 636 314473 63790 50226225
Glomerular filtration rate decreased 57.04 9.82 181 314928 11471 50278544
Glycosylated haemoglobin decreased 56.44 9.82 36 315073 446 50289569
Arthritis 55.84 9.82 314 314795 86407 50203608
Product odour abnormal 55.16 9.82 49 315060 1028 50288987
Mobility decreased 55.06 9.82 283 314826 79665 50210350
Insulin resistance 54.84 9.82 41 315068 667 50289348
Tenosynovitis 53.53 9.82 3 315106 10562 50279453
Atrioventricular block 53.37 9.82 122 314987 6356 50283659
Blood ketone body increased 52.44 9.82 28 315081 242 50289773
Renal tubular necrosis 51.66 9.82 160 314949 10008 50280007
Cholelithiasis 51.62 9.82 409 314700 37564 50252451
Amylase increased 51.24 9.82 108 315001 5322 50284693
Polydipsia 51.17 9.82 79 315030 3045 50286970
Haemodynamic instability 51.17 9.82 137 314972 7887 50282128
Rheumatoid nodule 50.72 9.82 9 315100 12726 50277289
Abdominal pain 50.54 9.82 1872 313237 234356 50055659
Loss of personal independence in daily activities 50.51 9.82 244 314865 69806 50220209
Oliguria 50.11 9.82 138 314971 8078 50281937
Affect lability 49.87 9.82 146 314963 8852 50281163
Exposure during pregnancy 49.73 9.82 1043 314066 119972 50170043
Thrombocytopenia 49.41 9.82 532 314577 127141 50162874
Drug level above therapeutic 49.27 9.82 88 315021 3832 50286183
Pneumonia 48.98 9.82 1894 313215 376507 49913508
C-reactive protein increased 48.83 9.82 230 314879 66244 50223771
Migraine 48.77 9.82 272 314837 75008 50215007
Blood potassium increased 48.72 9.82 217 314892 16181 50273834
White blood cell count decreased 47.76 9.82 480 314629 116242 50173773
Hypovolaemic shock 47.59 9.82 102 315007 5086 50284929
Macroangiopathy 47.48 9.82 20 315089 94 50289921
Anhidrosis 47.31 9.82 20 315089 95 50289920
Drug resistance 47.11 9.82 30 315079 18959 50271056
Device expulsion 46.47 9.82 67 315042 28755 50261260
Knee arthroplasty 46.23 9.82 96 315013 35750 50254265
Toothache 45.34 9.82 217 314892 16677 50273338
Therapy non-responder 45.30 9.82 164 314945 50858 50239157
Motor dysfunction 45.17 9.82 131 314978 7900 50282115
Cerebral venous thrombosis 45.15 9.82 57 315052 1814 50288201
Product prescribing error 45.00 9.82 253 314856 20708 50269307
Malaise 44.99 9.82 2536 312573 332996 49957019
Bone erosion 44.97 9.82 9 315100 11678 50278337
Lipase increased 44.89 9.82 136 314973 8405 50281610
Dialysis 44.73 9.82 145 314964 9293 50280722
Immune-mediated myositis 44.71 9.82 43 315066 1002 50289013
Suicide attempt 44.69 9.82 506 314603 51226 50238789
Leukopenia 44.29 9.82 243 314866 67285 50222730
Latent autoimmune diabetes in adults 43.69 9.82 13 315096 14 50290001
Myelosuppression 43.30 9.82 15 315094 13502 50276513
Pancreatic carcinoma metastatic 42.74 9.82 58 315051 1984 50288031
Diabetic nephropathy 42.62 9.82 47 315062 1292 50288723
Drug tolerance decreased 42.41 9.82 4 315105 9156 50280859
Eating disorder 42.13 9.82 199 314910 15210 50274805
Electrocardiogram T wave peaked 41.81 9.82 22 315087 184 50289831
Unresponsive to stimuli 41.78 9.82 330 314779 30279 50259736
Condition aggravated 40.81 9.82 1476 313633 295582 49994433
Multiple organ dysfunction syndrome 40.21 9.82 485 314624 49852 50240163
Transplant rejection 40.04 9.82 6 315103 9603 50280412
Glycosylated haemoglobin abnormal 39.84 9.82 17 315092 83 50289932
Multiple sclerosis relapse 39.54 9.82 136 314973 42828 50247187
Sensory loss 39.53 9.82 122 314987 7616 50282399
Seizure 39.49 9.82 507 314602 117367 50172648
Hyponatraemia 39.29 9.82 828 314281 95311 50194704
Tubulointerstitial nephritis 39.11 9.82 193 314916 15018 50274997
Bone marrow failure 39.09 9.82 70 315039 27554 50262461
Inflammation 38.87 9.82 202 314907 56710 50233305
Immunodeficiency 38.78 9.82 22 315087 14806 50275209
Red blood cell sedimentation rate increased 38.60 9.82 78 315031 29338 50260677
Myopathy 38.54 9.82 135 314974 9004 50281011
Neurotoxicity 38.37 9.82 22 315087 14718 50275297
Pneumocystis jirovecii pneumonia 38.00 9.82 22 315087 14641 50275374
Haematotoxicity 37.78 9.82 3 315106 7892 50282123
Hyperglycaemic hyperosmolar nonketotic syndrome 37.44 9.82 31 315078 589 50289426
Drug abuse 37.27 9.82 219 314890 59627 50230388
Haemophagocytic lymphohistiocytosis 36.89 9.82 5 315104 8628 50281387
Prerenal failure 36.85 9.82 46 315063 1447 50288568
Urine albumin/creatinine ratio abnormal 36.77 9.82 9 315100 0 50290015
Persistent cloaca 36.31 9.82 20 315089 185 50289830
Gastroenteritis 36.29 9.82 259 314850 23022 50266993
Adenocarcinoma pancreas 36.27 9.82 38 315071 984 50289031
Therapeutic response decreased 36.12 9.82 161 314948 47070 50242945
Pharyngitis 36.08 9.82 209 314900 17294 50272721
Foot deformity 35.81 9.82 40 315069 19170 50270845
Disease progression 35.28 9.82 404 314705 95462 50194553
Dysarthria 35.13 9.82 372 314737 37031 50252984
Distributive shock 34.88 9.82 34 315075 806 50289209
Blood triglycerides increased 34.59 9.82 151 314958 11161 50278854
Malignant neoplasm progression 34.56 9.82 265 314844 67859 50222156
Sopor 34.46 9.82 227 314882 19652 50270363
Left ventricular hypertrophy 34.26 9.82 86 315023 4759 50285256
Blood creatine phosphokinase increased 34.21 9.82 281 314828 26086 50263929
Exposure via ingestion 34.05 9.82 62 315047 2741 50287274
Neutrophil count decreased 33.94 9.82 159 314950 45867 50244148
Kussmaul respiration 33.84 9.82 20 315089 214 50289801
Injection site erythema 33.70 9.82 301 314808 74635 50215380
Injection site reaction 33.38 9.82 179 314930 49853 50240162
Product use in unapproved indication 33.18 9.82 514 314595 115305 50174710
Cerebrovascular accident 32.91 9.82 797 314312 93883 50196132
Decreased appetite 32.66 9.82 1547 313562 199376 50090639
Cold sweat 32.49 9.82 142 314967 10502 50279513
Product substitution issue 32.41 9.82 173 314936 13884 50276131
Allergic reaction to excipient 32.33 9.82 21 315088 269 50289746
Hospitalisation 31.83 9.82 270 314839 67667 50222348
Panniculitis 31.79 9.82 7 315102 8496 50281519
Bladder sphincter atony 31.73 9.82 17 315092 148 50289867
Accidental overdose 31.44 9.82 219 314890 19314 50270701
Type 2 diabetes mellitus 31.41 9.82 340 314769 34035 50255980
Albuminuria 31.41 9.82 18 315091 181 50289834
Platelet count decreased 31.28 9.82 440 314669 100286 50189729
Enthesopathy 31.13 9.82 4 315105 7189 50282826
Body mass index increased 30.92 9.82 35 315074 991 50289024
High density lipoprotein decreased 30.71 9.82 45 315064 1655 50288360
Blood pH decreased 30.71 9.82 55 315054 2400 50287615
Anaemia megaloblastic 30.69 9.82 21 315088 295 50289720
Pain in jaw 30.60 9.82 129 314980 38299 50251716
Cytokine release syndrome 30.53 9.82 8 315101 8626 50281389
Anaemia macrocytic 30.32 9.82 56 315053 2503 50287512
Haemofiltration 30.15 9.82 8 315101 3 50290012
Bladder cancer 29.98 9.82 65 315044 3267 50286748
Intestinal malrotation 29.79 9.82 22 315087 351 50289664
Suspected suicide 29.76 9.82 87 315022 5270 50284745
Osteoporosis 29.70 9.82 161 314948 44718 50245297
Pancreatitis chronic 29.40 9.82 51 315058 2169 50287846
Herpes zoster 29.40 9.82 290 314819 70496 50219519
Diabetic ketosis 29.24 9.82 17 315092 176 50289839
Posterior reversible encephalopathy syndrome 29.03 9.82 30 315079 14898 50275117
Blood pressure systolic increased 28.94 9.82 343 314766 35106 50254909
Vitamin B12 decreased 28.94 9.82 58 315051 2757 50287258
Mucosal inflammation 28.83 9.82 140 314969 40002 50250013
Insulin C-peptide decreased 28.41 9.82 9 315100 14 50290001
Pregnancy 28.33 9.82 92 315017 29485 50260530
Coronary artery disease 28.08 9.82 296 314813 29430 50260585
Hypophagia 28.05 9.82 280 314829 27448 50262567
Intentional product use issue 27.96 9.82 325 314784 76593 50213422
Hemiparesis 27.83 9.82 217 314892 19831 50270184
Pulmonary fibrosis 27.82 9.82 70 315039 24367 50265648
Blindness transient 27.81 9.82 62 315047 3176 50286839
Acute coronary syndrome 27.81 9.82 124 314985 9250 50280765
Lower respiratory tract infection 27.77 9.82 421 314688 94780 50195235
Headache 27.33 9.82 2750 312359 503785 49786230
Foreign body aspiration 27.21 9.82 15 315094 139 50289876
Blood lactic acid 26.76 9.82 13 315096 90 50289925
Infective pulmonary exacerbation of cystic fibrosis 26.71 9.82 8 315101 7901 50282114
Oedematous pancreatitis 26.59 9.82 21 315088 372 50289643
Osmolar gap 26.52 9.82 13 315096 92 50289923
Renal abscess 26.48 9.82 26 315083 622 50289393
Urinary tract discomfort 26.16 9.82 17 315092 218 50289797
Pancreatic mass 25.97 9.82 28 315081 750 50289265
Sedation complication 25.97 9.82 11 315098 8755 50281260
Progressive multifocal leukoencephalopathy 25.91 9.82 20 315089 11437 50278578
Conjoined twins 25.76 9.82 18 315091 262 50289753
Granuloma skin 25.76 9.82 3 315106 5815 50284200
Epstein-Barr virus infection 25.68 9.82 6 315103 6991 50283024
Diabetic hyperosmolar coma 25.58 9.82 20 315089 349 50289666
Glucose urine present 25.11 9.82 26 315083 664 50289351
Shock hypoglycaemic 25.09 9.82 13 315096 105 50289910
Pancreatic injury 24.96 9.82 9 315100 25 50289990
Aspergillus infection 24.73 9.82 6 315103 6815 50283200
Glomerular filtration rate abnormal 24.55 9.82 23 315086 518 50289497
Thrombotic microangiopathy 24.53 9.82 12 315097 8779 50281236
Pleural effusion 24.52 9.82 358 314751 81096 50208919
Mechanical ventilation complication 24.51 9.82 6 315103 0 50290015
Thirst 24.50 9.82 131 314978 10519 50279496
Dysentery 24.43 9.82 27 315082 744 50289271
Cholecystitis chronic 24.37 9.82 122 314987 9547 50280468
Mouth ulceration 24.26 9.82 91 315018 27933 50262082
Acute myocardial infarction 24.23 9.82 284 314825 28989 50261026
Skin ulcer 23.75 9.82 126 314983 35192 50254823
Temperature perception test abnormal 23.67 9.82 8 315101 17 50289998
Blood pressure systolic decreased 23.53 9.82 84 315025 5655 50284360
Hepatic function abnormal 23.45 9.82 114 314995 32567 50257448
Disability 23.38 9.82 27 315082 12748 50277267
Apolipoprotein A-I decreased 23.36 9.82 8 315101 18 50289997
Hyperinsulinaemia 23.36 9.82 12 315097 95 50289920
Malabsorption 23.35 9.82 63 315046 3643 50286372
Hyperinsulinaemic hypoglycaemia 23.25 9.82 10 315099 50 50289965
Polymyalgia rheumatica 23.23 9.82 51 315058 2585 50287430
Anovulatory cycle 22.91 9.82 13 315096 128 50289887
Gastrointestinal disorder 22.90 9.82 432 314677 94024 50195991
Blood insulin decreased 22.87 9.82 7 315102 9 50290006
Basal cell carcinoma 22.82 9.82 72 315037 23284 50266731
Cleft lip 22.74 9.82 12 315097 101 50289914
IIIrd nerve paresis 22.66 9.82 13 315096 131 50289884
Macular degeneration 22.65 9.82 34 315075 14354 50275661
Blood growth hormone increased 22.62 9.82 20 315089 417 50289598
Body temperature decreased 22.50 9.82 177 314932 16218 50273797
Cholestatic liver injury 22.42 9.82 43 315066 1978 50288037
Hypoglycaemic unconsciousness 22.39 9.82 25 315084 697 50289318
Gait inability 22.26 9.82 339 314770 36688 50253327
Hypovolaemia 22.17 9.82 117 314992 9348 50280667
Ulcer 22.13 9.82 59 315050 20141 50269874
Congenital absence of bile ducts 21.99 9.82 8 315101 23 50289992
Macular oedema 21.91 9.82 61 315048 3593 50286422
Adverse event 21.84 9.82 171 314938 43592 50246423
Pruritus genital 21.72 9.82 23 315086 603 50289412
Non-alcoholic steatohepatitis 21.72 9.82 35 315074 1400 50288615
Blood phosphorus increased 21.68 9.82 49 315060 2533 50287482
Asthenia 21.65 9.82 2286 312823 316756 49973259
Base excess negative 21.47 9.82 6 315103 4 50290011
Unintentional medical device removal 21.30 9.82 4 315105 5431 50284584
Stevens-Johnson syndrome 21.29 9.82 67 315042 21685 50268330
Aphasia 21.23 9.82 271 314838 28223 50261792
Swollen tongue 21.20 9.82 272 314837 28358 50261657
Hyperhidrosis 21.14 9.82 717 314392 88709 50201306
Diabetic foot 21.13 9.82 33 315076 1285 50288730
Bursitis 21.10 9.82 69 315040 22066 50267949
Carcinoid tumour of the stomach 21.09 9.82 13 315096 151 50289864
Fungal infection 21.07 9.82 282 314827 29683 50260332
Overweight 21.01 9.82 54 315055 3032 50286983
Blood urea increased 20.96 9.82 232 314877 23353 50266662
Pollakiuria 20.91 9.82 234 314875 23617 50266398
Necrotising myositis 20.89 9.82 18 315091 362 50289653
Complication associated with device 20.86 9.82 37 315072 14618 50275397
Lymphopenia 20.85 9.82 41 315068 15580 50274435
Jaundice hepatocellular 20.82 9.82 8 315101 28 50289987
Mitochondrial enzyme deficiency 20.82 9.82 8 315101 28 50289987
Increased appetite 20.73 9.82 105 315004 8256 50281759
Bone density decreased 20.71 9.82 23 315086 11052 50278963
Sedation 20.70 9.82 109 315000 30501 50259514
Constipation 20.69 9.82 945 314164 184763 50105252
Pathogen resistance 20.64 9.82 5 315104 5684 50284331
Postmenopausal haemorrhage 20.60 9.82 41 315068 1939 50288076
Metabolic syndrome 20.59 9.82 33 315076 1314 50288701
Urine output decreased 20.55 9.82 123 314986 10298 50279717
Generalised tonic-clonic seizure 20.53 9.82 89 315020 26221 50263794
Hepatosplenomegaly neonatal 20.43 9.82 5 315104 0 50290015
Multiple cardiac defects 20.43 9.82 5 315104 0 50290015
CD30 expression 20.40 9.82 8 315101 30 50289985
Diabetic ulcer 20.38 9.82 14 315095 198 50289817
Bronchopulmonary aspergillosis 20.24 9.82 11 315098 7581 50282434
Febrile bone marrow aplasia 20.22 9.82 7 315102 6304 50283711
Ischaemic stroke 20.17 9.82 169 314940 15779 50274236
Needle issue 19.92 9.82 94 315015 7181 50282834
Lymphocyte count decreased 19.92 9.82 90 315019 26217 50263798
Oxygen saturation immeasurable 19.92 9.82 6 315103 7 50290008
Resuscitation 19.87 9.82 28 315081 993 50289022
Congenital bladder anomaly 19.72 9.82 13 315096 171 50289844
Dry eye 19.69 9.82 118 314991 31977 50258038
Coordination abnormal 19.56 9.82 131 314978 11403 50278612
Osmolar gap increased 19.53 9.82 7 315102 19 50289996
Bronchostenosis 19.49 9.82 18 315091 398 50289617
Cytomegalovirus viraemia 19.48 9.82 3 315106 4706 50285309
Dizziness 19.48 9.82 2452 312657 343917 49946098
Blood parathyroid hormone decreased 19.42 9.82 10 315099 7104 50282911
Urachal abnormality 19.22 9.82 13 315096 179 50289836
Epileptic encephalopathy 19.22 9.82 15 315094 261 50289754
Pulseless electrical activity 19.18 9.82 89 315020 6752 50283263
Hypoparathyroidism 19.17 9.82 21 315088 573 50289442
Prothrombin consumption time prolonged 19.09 9.82 8 315101 37 50289978
Systemic infection 18.81 9.82 43 315066 2240 50287775
Oral herpes 18.80 9.82 66 315043 20659 50269356
Metastases to retroperitoneum 18.79 9.82 12 315097 149 50289866
Hyperphagia 18.75 9.82 34 315075 1498 50288517
Peritonitis 18.71 9.82 43 315066 15443 50274572
Choreoathetosis 18.59 9.82 18 315091 423 50289592
Crush syndrome 18.59 9.82 11 315098 118 50289897
Decreased bronchial secretion 18.56 9.82 9 315100 62 50289953
Lupus-like syndrome 18.54 9.82 19 315090 9472 50280543
Lung disorder 18.40 9.82 184 314925 44615 50245400
Thalamic infarction 18.38 9.82 18 315091 429 50289586
Congenital aortic valve stenosis 18.33 9.82 9 315100 64 50289951
Insulin-like growth factor increased 18.30 9.82 24 315085 794 50289221
Joint stiffness 18.29 9.82 112 314997 30196 50259819
No adverse event 18.28 9.82 128 314981 33450 50256565
Hypervolaemia 18.27 9.82 89 315020 25410 50264605
Herpes simplex 18.20 9.82 11 315098 7151 50282864
Fibromyalgia 17.96 9.82 186 314923 44792 50245223
Immune reconstitution inflammatory syndrome 17.88 9.82 6 315103 5510 50284505
Thyroglobulin increased 17.83 9.82 8 315101 45 50289970
Base excess decreased 17.76 9.82 9 315100 69 50289946
Osteonecrosis of jaw 17.71 9.82 124 314985 32402 50257613
Blood ketone body 17.69 9.82 8 315101 46 50289969
Blood cholesterol increased 17.56 9.82 240 314869 54975 50235040
Basilar artery thrombosis 17.54 9.82 11 315098 132 50289883
Creatinine renal clearance 17.51 9.82 5 315104 4 50290011
Genital infection fungal 17.51 9.82 12 315097 169 50289846
Poisoning 17.51 9.82 135 314974 12294 50277721
Joint range of motion decreased 17.44 9.82 58 315051 18454 50271561
Accidental underdose 17.42 9.82 21 315088 637 50289378
Neuropathy, ataxia, retinitis pigmentosa syndrome 17.41 9.82 8 315101 48 50289967
Nephrogenic systemic fibrosis 17.33 9.82 3 315106 4319 50285696
Acute myeloid leukaemia 17.30 9.82 43 315066 15031 50274984
Atrioventricular block complete 17.21 9.82 90 315019 7165 50282850
Pancreatic enzymes increased 17.16 9.82 21 315088 647 50289368
Colitis ulcerative 17.15 9.82 51 315058 16803 50273212
Creatinine renal clearance abnormal 17.13 9.82 16 315093 359 50289656
Thyroid cancer recurrent 17.13 9.82 7 315102 30 50289985
Bicuspid aortic valve 17.08 9.82 10 315099 105 50289910
Clostridium difficile infection 16.97 9.82 91 315018 25348 50264667
Eyelid bleeding 16.95 9.82 7 315102 31 50289984
Autoimmune myositis 16.93 9.82 9 315100 77 50289938
Device related infection 16.89 9.82 69 315040 20666 50269349
Dyslipidaemia 16.86 9.82 78 315031 5910 50284105
Body temperature increased 16.81 9.82 120 314989 31221 50258794
Hypertensive heart disease 16.80 9.82 41 315068 2229 50287786
Metastases to kidney 16.76 9.82 12 315097 182 50289833
Musculoskeletal disorder 16.59 9.82 54 315055 17295 50272720
Renal injury 16.58 9.82 101 315008 8510 50281505
Pulmonary hypoplasia 16.48 9.82 14 315095 276 50289739
Tinnitus 16.44 9.82 105 315004 28027 50261988
Product complaint 16.41 9.82 125 314984 11341 50278674
Differential white blood cell count abnormal 16.40 9.82 21 315088 678 50289337
Hyperventilation 16.38 9.82 72 315037 5337 50284678
Hypoglycaemia neonatal 16.35 9.82 24 315085 884 50289131
Skinfold measurement 16.34 9.82 4 315105 0 50290015
Labelled drug-disease interaction issue 16.34 9.82 4 315105 0 50290015
Pleural mesothelioma 16.34 9.82 4 315105 0 50290015
Reactive psychosis 16.34 9.82 4 315105 0 50290015
Blood lactic acid abnormal 16.34 9.82 4 315105 0 50290015
Myxoedema coma 16.29 9.82 16 315093 383 50289632
Persistent left superior vena cava 16.27 9.82 7 315102 35 50289980
Hyperphosphataemia 16.27 9.82 36 315073 1835 50288180
Wrong patient received product 16.26 9.82 34 315075 1666 50288349
Disease recurrence 16.24 9.82 67 315042 20014 50270001
Medullary thyroid cancer 16.24 9.82 10 315099 116 50289899
Congenital uterine anomaly 16.24 9.82 10 315099 116 50289899
Adrenal adenoma 16.23 9.82 23 315086 820 50289195
Anion gap abnormal 16.15 9.82 15 315094 334 50289681
Device dislocation 16.14 9.82 74 315035 21472 50268543
Sprue-like enteropathy 16.03 9.82 18 315091 505 50289510
Grip strength decreased 16.02 9.82 32 315077 12089 50277926
Renal tubular disorder 15.93 9.82 42 315067 2395 50287620
Night sweats 15.92 9.82 133 314976 33441 50256574
Antipsychotic drug level increased 15.87 9.82 49 315060 3060 50286955
Skin necrosis 15.86 9.82 27 315082 10840 50279175
Joint effusion 15.85 9.82 36 315073 12985 50277030
Skin haemorrhage 15.85 9.82 85 315024 6833 50283182
Flushing 15.78 9.82 308 314801 66707 50223308
Cutaneous T-cell dyscrasia 15.72 9.82 8 315101 62 50289953
Glycosuria 15.64 9.82 26 315083 1068 50288947
Visceral congestion 15.59 9.82 14 315095 298 50289717
Monoclonal B-cell lymphocytosis 15.52 9.82 7 315102 40 50289975
Drug eruption 15.44 9.82 85 315024 23521 50266494
Inappropriate antidiuretic hormone secretion 15.43 9.82 137 314972 13006 50277009
Premature labour 15.42 9.82 30 315079 11446 50278569
Blood pressure inadequately controlled 15.38 9.82 61 315048 4319 50285696
Catheter site erythema 15.35 9.82 3 315106 3959 50286056
Intestinal perforation 15.33 9.82 26 315083 10453 50279562
Urine albumin/creatinine ratio increased 15.32 9.82 12 315097 210 50289805
Incorrect route of product administration 15.27 9.82 62 315047 18604 50271411
Pyelonephritis acute 15.26 9.82 58 315051 4025 50285990
Incorrect dose administered 15.18 9.82 402 314707 48012 50242003
Neuroendocrine tumour 15.08 9.82 18 315091 540 50289475
Alkalosis hypochloraemic 15.08 9.82 10 315099 133 50289882
Malignant mediastinal neoplasm 14.93 9.82 18 315091 546 50289469
Osteonecrosis 14.77 9.82 81 315028 22436 50267579
Alveolar osteitis 14.77 9.82 16 315093 431 50289584
Hyponatraemic encephalopathy 14.76 9.82 12 315097 222 50289793
Premature delivery 14.75 9.82 218 314891 23445 50266570
Angina pectoris 14.69 9.82 237 314872 25951 50264064
Muscle necrosis 14.64 9.82 17 315092 495 50289520
Pancreatic atrophy 14.46 9.82 10 315099 143 50289872
Blood pressure diastolic decreased 14.42 9.82 164 314945 16617 50273398
Optic neuritis 14.38 9.82 13 315096 6877 50283138
Transcription medication error 14.36 9.82 11 315098 186 50289829
Staphylococcal infection 14.33 9.82 147 314962 35469 50254546
Foetal hypokinesia 14.30 9.82 16 315093 447 50289568
Confusional state 14.29 9.82 1344 313765 184584 50105431
Diabetic ketoacidotic hyperglycaemic coma 14.23 9.82 7 315102 50 50289965
Diabetic cheiroarthropathy 14.12 9.82 4 315105 3 50290012
Diabetes mellitus management 14.12 9.82 4 315105 3 50290012
Medication error 14.11 9.82 309 314800 35795 50254220
Treatment noncompliance 14.09 9.82 265 314844 29885 50260130
Status epilepticus 14.05 9.82 40 315069 13366 50276649
Device difficult to use 14.03 9.82 25 315084 9861 50280154
Gallbladder oedema 14.02 9.82 11 315098 193 50289822
Mental disability 14.00 9.82 8 315101 80 50289935
Retinal artery thrombosis 13.91 9.82 8 315101 81 50289934
Pelvic fracture 13.91 9.82 32 315077 11488 50278527
Cortisol increased 13.89 9.82 14 315095 346 50289669
Hypertensive crisis 13.87 9.82 134 314975 13020 50276995
Hypertensive angiopathy 13.83 9.82 8 315101 82 50289933
Blood growth hormone abnormal 13.79 9.82 6 315103 31 50289984
Erythema 13.79 9.82 758 314351 145656 50144359
Salivary hypersecretion 13.78 9.82 79 315030 6512 50283503
Musculoskeletal pain 13.75 9.82 343 314766 71834 50218181
Blood electrolytes abnormal 13.74 9.82 23 315086 950 50289065
Diaphragmatic spasm 13.59 9.82 4 315105 4 50290011
Venous aneurysm 13.59 9.82 4 315105 4 50290011
Skin turgor decreased 13.59 9.82 16 315093 473 50289542
PCO2 decreased 13.59 9.82 26 315083 1194 50288821
Abnormal loss of weight 13.55 9.82 65 315044 4999 50285016
Obesity 13.55 9.82 162 314947 16613 50273402
Injection site swelling 13.49 9.82 181 314928 41592 50248423
Enterochromaffin cell hyperplasia 13.46 9.82 7 315102 57 50289958
Eructation 13.38 9.82 83 315026 7038 50282977
Low density lipoprotein increased 13.37 9.82 70 315039 5576 50284439
Psoriatic arthropathy 13.36 9.82 209 314900 46823 50243192
Cardiovascular disorder 13.34 9.82 111 314998 10343 50279672
Transient ischaemic attack 13.34 9.82 278 314831 31932 50258083
Rash maculo-papular 13.33 9.82 104 315005 26537 50263478
Hypereosinophilic syndrome 13.30 9.82 12 315097 257 50289758
Multiple sclerosis 13.29 9.82 74 315035 20419 50269596
Vision blurred 13.28 9.82 608 314501 78039 50211976
Blood cholesterol decreased 13.24 9.82 20 315089 756 50289259
Urosepsis 13.23 9.82 151 314958 15314 50274701
Brain stem infarction 13.22 9.82 20 315089 757 50289258
Sensorimotor disorder 13.13 9.82 15 315094 429 50289586
Drug half-life increased 13.12 9.82 5 315104 17 50289998
Flatulence 13.11 9.82 257 314852 29201 50260814
Autoimmune nephritis 13.10 9.82 13 315096 315 50289700
Anal incontinence 13.10 9.82 119 314990 11371 50278644
Adrenal neoplasm 13.00 9.82 13 315096 318 50289697
Unevaluable event 12.99 9.82 205 314904 45861 50244154
Femur fracture 12.96 9.82 160 314949 37304 50252711
Respiratory tract infection 12.94 9.82 132 314977 31885 50258130
Sinus arrest 12.92 9.82 31 315078 1667 50288348
Prescription drug used without a prescription 12.90 9.82 31 315078 1669 50288346
Red cell distribution width abnormal 12.88 9.82 9 315100 131 50289884
Ascites 12.84 9.82 152 314957 35709 50254306
Atrial fibrillation 12.81 9.82 765 314344 100980 50189035
Diet failure 12.79 9.82 6 315103 38 50289977
Tumour compression 12.79 9.82 6 315103 38 50289977
Lymphadenopathy 12.78 9.82 140 314969 33359 50256656
Bladder neoplasm 12.75 9.82 16 315093 506 50289509
Binge eating 12.75 9.82 14 315095 383 50289632
Bone pain 12.71 9.82 212 314897 47017 50242998
Peripheral artery haematoma 12.66 9.82 6 315103 39 50289976
Electrolyte imbalance 12.66 9.82 163 314946 17006 50273009
Muscular weakness 12.65 9.82 718 314391 94295 50195720
Hypergastrinaemia 12.62 9.82 8 315101 98 50289917
Hepatic cirrhosis 12.60 9.82 166 314943 17411 50272604
Blood iron decreased 12.59 9.82 119 314990 11496 50278519
Left atrial dilatation 12.52 9.82 31 315078 1701 50288314
Atelectasis 12.39 9.82 65 315044 18205 50271810
Anion gap 12.38 9.82 24 315085 1113 50288902
Rash erythematous 12.38 9.82 148 314961 34704 50255311
Spinal compression fracture 12.38 9.82 39 315070 12617 50277398
Blood osmolarity abnormal 12.34 9.82 4 315105 7 50290008
Cell death 12.33 9.82 36 315073 2179 50287836
Haemoglobin increased 12.27 9.82 45 315064 3070 50286945
Diffuse idiopathic skeletal hyperostosis 12.26 9.82 3 315106 0 50290015
Bladder pain 12.26 9.82 30 315079 1634 50288381
Nipple swelling 12.26 9.82 3 315106 0 50290015
Insulin resistant diabetes 12.26 9.82 3 315106 0 50290015
Non-high-density lipoprotein cholesterol decreased 12.26 9.82 3 315106 0 50290015
Fluid intake reduced 12.21 9.82 45 315064 3077 50286938
Tumour lysis syndrome 12.21 9.82 17 315092 7404 50282611
Device use error 12.16 9.82 9 315100 5257 50284758
Ear pain 12.11 9.82 115 314994 28168 50261847
Pneumonia aspiration 12.05 9.82 129 314980 30875 50259140
Injection site mass 12.05 9.82 150 314959 15530 50274485
Neurofibrosarcoma 12.01 9.82 9 315100 147 50289868
Glycosylated haemoglobin 12.00 9.82 7 315102 73 50289942
Ectopia cordis 12.00 9.82 7 315102 73 50289942
Vitamin B6 deficiency 12.00 9.82 7 315102 73 50289942
Gingival oedema 12.00 9.82 7 315102 73 50289942
Cholangiectasis acquired 12.00 9.82 4 315105 8 50290007
Foreign body in reproductive tract 11.96 9.82 15 315094 474 50289541
Blood lactate dehydrogenase increased 11.96 9.82 72 315037 19490 50270525
Psychogenic tremor 11.96 9.82 5 315104 23 50289992
Skin disorder 11.94 9.82 94 315015 23936 50266079
Pneumonia viral 11.91 9.82 15 315094 6819 50283196
Chorea 11.90 9.82 26 315083 1314 50288701
Duodenal ulcer haemorrhage 11.86 9.82 35 315074 2131 50287884
Nodular rash 11.86 9.82 10 315099 195 50289820
Parkinsonism 11.86 9.82 95 315014 8752 50281263
Product blister packaging issue 11.86 9.82 9 315100 150 50289865
Heart sounds 11.85 9.82 17 315092 613 50289402
Multiple-drug resistance 11.85 9.82 3 315106 3311 50286704
Demyelination 11.84 9.82 12 315097 6014 50284001
Retinopathy proliferative 11.84 9.82 6 315103 46 50289969
Product size issue 11.83 9.82 12 315097 299 50289716
Pyelonephritis 11.78 9.82 144 314965 14845 50275170
Hyperparathyroidism secondary 11.76 9.82 26 315083 1324 50288691
Food craving 11.74 9.82 27 315082 1412 50288603
Pancreatic neoplasm 11.69 9.82 18 315091 692 50289323
Cutaneous vasculitis 11.68 9.82 56 315053 4306 50285709
Intentional self-injury 11.67 9.82 90 315019 23022 50266993
Retching 11.65 9.82 127 314982 12735 50277280
Maternal exposure timing unspecified 11.63 9.82 4 315105 3616 50286399
Urinary tract infection 11.57 9.82 1578 313531 222442 50067573
Clostridium difficile colitis 11.54 9.82 64 315045 17678 50272337
Tunnel vision 11.52 9.82 18 315091 701 50289314
Duodenal ulcer 11.52 9.82 77 315032 6698 50283317
Large intestine perforation 11.52 9.82 18 315091 7476 50282539
Electrocardiogram abnormal 11.50 9.82 84 315025 7521 50282494
Dystonia 11.49 9.82 37 315072 11889 50278126
Prolonged expiration 11.49 9.82 18 315091 703 50289312
Diffuse large B-cell lymphoma 11.45 9.82 11 315098 5651 50284364
Coronary artery occlusion 11.42 9.82 83 315026 7420 50282595
Respiratory syncytial virus infection 11.42 9.82 9 315100 5093 50284922
Coeliac disease 11.42 9.82 23 315086 8662 50281353
Intestinal obstruction 11.41 9.82 107 315002 26276 50263739
Blood calcium decreased 11.24 9.82 79 315030 20627 50269388
Chronic sinusitis 11.23 9.82 13 315096 6132 50283883
Serotonin syndrome 11.22 9.82 99 315010 24614 50265401
Ankylosing spondylitis 11.21 9.82 17 315092 7148 50282867
Genital rash 11.20 9.82 14 315095 441 50289574
Genital swelling 11.19 9.82 8 315101 121 50289894
Myocardial ischaemia 11.14 9.82 116 314993 11497 50278518
Bradyphrenia 11.12 9.82 71 315038 6081 50283934
Erythromelalgia 11.08 9.82 8 315101 123 50289892
Diabetic foot infection 11.05 9.82 9 315100 167 50289848
Hypertriglyceridaemia 10.95 9.82 65 315044 5426 50284589
Neutropenic sepsis 10.95 9.82 48 315061 14099 50275916
Product administration error 10.95 9.82 178 314931 19521 50270494
Central nervous system lesion 10.94 9.82 27 315082 9462 50280553
Metastases to central nervous system 10.87 9.82 35 315074 11247 50278768
Microcytic anaemia 10.87 9.82 43 315066 3041 50286974
Lactate pyruvate ratio increased 10.82 9.82 7 315102 89 50289926
Urine output increased 10.81 9.82 23 315086 1141 50288874
Bradyarrhythmia 10.79 9.82 31 315078 1859 50288156
Grandiosity 10.78 9.82 11 315098 276 50289739
Vascular device infection 10.77 9.82 7 315102 4377 50285638
Blood chloride decreased 10.73 9.82 60 315049 4901 50285114
Impaired work ability 10.70 9.82 131 314978 13509 50276506
Blood insulin increased 10.66 9.82 8 315101 131 50289884
Urine ketone body 10.66 9.82 8 315101 131 50289884
Aerophagia 10.63 9.82 4 315105 13 50290002
Pneumothorax 10.63 9.82 48 315061 13986 50276029
Biopsy skin abnormal 10.62 9.82 7 315102 92 50289923
Cerebellar ischaemia 10.62 9.82 5 315104 32 50289983
Malignant polyp 10.61 9.82 9 315100 177 50289838
Macrosomia 10.58 9.82 6 315103 59 50289956
Early satiety 10.57 9.82 18 315091 754 50289261
Pulmonary haemorrhage 10.56 9.82 15 315094 6477 50283538
Large intestine polyp 10.53 9.82 80 315029 7252 50282763
Genital infection female 10.50 9.82 7 315102 94 50289921
Increased tendency to bruise 10.50 9.82 27 315082 9329 50280686
Empty sella syndrome 10.49 9.82 5 315104 33 50289982
Hypogammaglobulinaemia 10.48 9.82 12 315097 5687 50284328
Deformity 10.46 9.82 21 315088 7919 50282096
Metabolic encephalopathy 10.46 9.82 61 315048 5060 50284955
Pleural fibrosis 10.43 9.82 4 315105 3380 50286635
Synovial cyst 10.42 9.82 22 315087 8144 50281871
Insulin C-peptide increased 10.41 9.82 6 315103 61 50289954
Glucose urine 10.41 9.82 4 315105 14 50290001
Glomerular filtration rate increased 10.40 9.82 12 315097 347 50289668
Drug reaction with eosinophilia and systemic symptoms 10.36 9.82 120 314989 28304 50261711
Blindness 10.34 9.82 158 314951 17111 50272904
Wrong dose 10.31 9.82 19 315090 848 50289167
Vitreous haemorrhage 10.30 9.82 29 315080 1719 50288296
Gastrointestinal carcinoma 10.29 9.82 26 315083 1445 50288570
Hypertensive emergency 10.28 9.82 27 315082 1536 50288479
Blood pressure abnormal 10.25 9.82 123 314986 12624 50277391
Retinal vascular disorder 10.24 9.82 9 315100 186 50289829
CSF volume increased 10.20 9.82 3 315106 3 50290012
Aerococcus urinae infection 10.20 9.82 3 315106 3 50290012
Ovarian cyst torsion 10.20 9.82 3 315106 3 50290012
Castleman's disease 10.20 9.82 3 315106 3 50290012
Clear cell endometrial carcinoma 10.20 9.82 3 315106 3 50290012
Accidental exposure to product 10.19 9.82 93 315016 22964 50267051
Fat tissue increased 10.19 9.82 15 315094 554 50289461
Encephalitis 10.17 9.82 19 315090 7361 50282654
Hormone level abnormal 10.17 9.82 33 315076 2116 50287899
Diabetic complication 10.14 9.82 18 315091 780 50289235
Pancreatic failure 10.14 9.82 19 315090 859 50289156
Bundle branch block left 10.11 9.82 70 315039 6160 50283855
Scleroderma 10.09 9.82 9 315100 4792 50285223
Hypoplastic left heart syndrome 10.09 9.82 9 315100 190 50289825
Purpura 10.08 9.82 30 315079 9881 50280134
Thirst decreased 10.02 9.82 10 315099 244 50289771
Endoscopy upper gastrointestinal tract 10.02 9.82 5 315104 37 50289978
Dyskinesia 10.01 9.82 118 314991 27743 50262272
Oxygen saturation decreased 10.01 9.82 364 314745 72884 50217131
Insulin-like growth factor decreased 10.00 9.82 12 315097 362 50289653
Hypocalcaemia 10.00 9.82 228 314881 26588 50263427
Aplasia pure red cell 10.00 9.82 7 315102 4208 50285807
Acute hepatic failure 9.95 9.82 57 315052 15620 50274395
Vulvovaginal mycotic infection 9.94 9.82 55 315054 4474 50285541
Foetal macrosomia 9.94 9.82 6 315103 67 50289948
Vulvovaginitis 9.93 9.82 11 315098 304 50289711
Lichen planus 9.92 9.82 31 315078 1948 50288067
Exercise tolerance decreased 9.92 9.82 58 315051 4816 50285199
Tuberculosis 9.91 9.82 31 315078 10052 50279963
Neck pain 9.87 9.82 275 314834 56792 50233223
Transfusion 9.86 9.82 44 315065 12861 50277154
Coma scale abnormal 9.85 9.82 57 315052 4714 50285301
Glucose tolerance impaired 9.83 9.82 60 315049 5058 50284957

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 9490.52 10.83 4890 264495 25357 29279785
Hypoglycaemia 1866.39 10.83 2250 267135 46096 29259046
Acute kidney injury 1850.84 10.83 5949 263436 259318 29045824
Diabetic ketoacidosis 1456.08 10.83 1192 268193 14881 29290261
Metabolic acidosis 1409.28 10.83 1726 267659 35936 29269206
Blood glucose increased 1061.00 10.83 1916 267469 57068 29248074
Euglycaemic diabetic ketoacidosis 716.70 10.83 388 268997 2242 29302900
Glycosylated haemoglobin increased 688.19 10.83 618 268767 8808 29296334
Diabetes mellitus inadequate control 672.05 10.83 683 268702 11451 29293691
Hyperkalaemia 626.42 10.83 1584 267801 59808 29245334
Pancreatitis 472.41 10.83 1000 268385 33514 29271628
Ketoacidosis 459.40 10.83 329 269056 3310 29301832
Hyperglycaemia 389.11 10.83 922 268463 33365 29271777
Pancreatitis acute 348.16 10.83 719 268666 23666 29281476
Off label use 345.20 10.83 1490 267895 299310 29005832
Hyperlactacidaemia 337.78 10.83 242 269143 2436 29302706
Drug abuse 302.40 10.83 176 269209 79707 29225435
Pemphigoid 264.82 10.83 336 269049 7245 29297897
Diabetic metabolic decompensation 260.89 10.83 162 269223 1254 29303888
Shock 255.25 10.83 587 268798 20817 29284325
Blood lactic acid increased 239.55 10.83 279 269106 5487 29299655
Febrile neutropenia 237.52 10.83 411 268974 111829 29193313
Death 214.00 10.83 2040 267345 340044 28965098
Hypoglycaemic coma 213.95 10.83 169 269216 1994 29303148
Blood glucose abnormal 207.91 10.83 244 269141 4839 29300303
Completed suicide 207.24 10.83 1470 267915 88776 29216366
Neutropenia 200.34 10.83 578 268807 131133 29174009
Pyrexia 196.39 10.83 1677 267708 285945 29019197
Pancreatic carcinoma 187.77 10.83 276 269109 6874 29298268
Drug ineffective 175.48 10.83 2296 267089 360874 28944268
Pneumonia 172.83 10.83 1976 267409 318196 28986946
Intentional overdose 170.07 10.83 749 268636 37779 29267363
Blood glucose decreased 167.69 10.83 352 269033 11717 29293425
Blood glucose fluctuation 166.32 10.83 184 269201 3413 29301729
Product use in unapproved indication 161.95 10.83 343 269042 86532 29218610
Anuria 136.91 10.83 282 269103 9259 29295883
Acidosis 135.93 10.83 284 269101 9421 29295721
Cytomegalovirus infection 133.14 10.83 25 269360 23190 29281952
Bladder cancer 128.81 10.83 285 269100 9842 29295300
Platelet count decreased 125.97 10.83 508 268877 104164 29200978
Vitamin B12 deficiency 125.52 10.83 152 269233 3119 29302023
Ketonuria 123.99 10.83 73 269312 507 29304635
Thrombocytopenia 123.04 10.83 722 268663 134101 29171041
Pancytopenia 112.22 10.83 385 269000 82783 29222359
Diabetic neuropathy 112.01 10.83 154 269231 3599 29301543
White blood cell count decreased 108.40 10.83 392 268993 82970 29222172
Leukopenia 107.03 10.83 213 269172 54990 29250152
Weight decreased 105.34 10.83 1945 267440 148960 29156182
Drug resistance 104.42 10.83 33 269352 21507 29283635
Continuous haemodiafiltration 103.64 10.83 79 269306 881 29304261
Seizure 102.78 10.83 467 268918 92656 29212486
Vomiting 99.12 10.83 2582 266803 209678 29095464
Bone marrow failure 96.18 10.83 66 269319 27383 29277759
Anion gap increased 94.94 10.83 93 269292 1487 29303655
Renal failure 94.70 10.83 1562 267823 117037 29188105
Infusion related reaction 94.27 10.83 159 269226 43727 29261415
Diabetes mellitus 93.74 10.83 653 268732 39178 29265964
Toxicity to various agents 90.70 10.83 2145 267240 171516 29133626
Disease progression 89.07 10.83 413 268972 81503 29223639
Immune-mediated myositis 88.30 10.83 90 269295 1513 29303629
Type 2 diabetes mellitus 86.88 10.83 297 269088 13284 29291858
Treatment failure 85.81 10.83 127 269258 36812 29268330
Drug dependence 84.01 10.83 43 269342 20938 29284204
Injection site nodule 83.65 10.83 84 269301 1386 29303756
Haemodialysis 80.47 10.83 236 269149 9718 29295424
Diarrhoea 80.13 10.83 3749 265636 328949 28976193
Stomatitis 78.29 10.83 136 269249 36977 29268165
Hypomagnesaemia 78.11 10.83 341 269044 17127 29288015
Ketosis 76.93 10.83 48 269337 375 29304767
Malignant neoplasm progression 75.29 10.83 381 269004 73478 29231664
Neutrophil count decreased 74.62 10.83 180 269205 43387 29261755
Pneumocystis jirovecii pneumonia 72.41 10.83 31 269354 16748 29288394
Toxic epidermal necrolysis 71.50 10.83 38 269347 18115 29287027
Graft versus host disease 71.36 10.83 4 269381 9624 29295518
Product residue present 69.56 10.83 100 269285 2439 29302703
Lipase increased 68.68 10.83 199 269186 8138 29297004
Drug level increased 68.08 10.83 345 269040 18442 29286700
Urine ketone body present 67.33 10.83 64 269321 984 29304158
MELAS syndrome 65.49 10.83 20 269365 11 29305131
Glomerular filtration rate decreased 64.87 10.83 238 269147 11028 29294114
Blood lactic acid 64.79 10.83 40 269345 306 29304836
Polyuria 63.83 10.83 179 269206 7183 29297959
Dehydration 62.79 10.83 1427 267958 113321 29191821
Distributive shock 61.10 10.83 59 269326 926 29304216
Myocardial infarction 60.46 10.83 1372 268013 108924 29196218
Neuropathy peripheral 58.68 10.83 392 268993 70635 29234507
Hypothermia 58.18 10.83 201 269184 9038 29296104
Bronchopulmonary aspergillosis 57.92 10.83 20 269365 12324 29292818
Suspected suicide 57.89 10.83 119 269266 3901 29301241
Overdose 57.75 10.83 1035 268350 78784 29226358
Macroangiopathy 56.60 10.83 16 269369 3 29305139
Pancreatic carcinoma metastatic 56.10 10.83 94 269291 2627 29302515
Blood pH decreased 55.51 10.83 82 269303 2051 29303091
Intentional product use issue 55.09 10.83 200 269185 42298 29262844
Myocardial ischaemia 55.06 10.83 290 269095 15738 29289404
Transplant rejection 54.83 10.83 9 269376 9203 29295939
Diabetic retinopathy 54.36 10.83 70 269315 1532 29303610
Posterior reversible encephalopathy syndrome 52.91 10.83 9 269376 8967 29296175
Anxiety 52.18 10.83 511 268874 84854 29220288
Toe amputation 52.04 10.83 80 269305 2075 29303067
Exposure via ingestion 51.69 10.83 77 269308 1941 29303201
Aspergillus infection 51.66 10.83 16 269369 10565 29294577
Pancreatitis chronic 51.40 10.83 77 269308 1951 29303191
Hepatic function abnormal 50.73 10.83 185 269200 39074 29266068
Hypotension 50.71 10.83 2209 267176 192145 29112997
Suicide attempt 49.62 10.83 502 268883 33608 29271534
Acetonaemia 49.51 10.83 25 269360 122 29305020
Alanine aminotransferase increased 49.32 10.83 411 268974 70533 29234609
Product odour abnormal 49.31 10.83 44 269341 621 29304521
Aggression 48.94 10.83 163 269222 35378 29269764
Kidney transplant rejection 48.74 10.83 4 269381 7001 29298141
Latent autoimmune diabetes in adults 48.29 10.83 18 269367 33 29305109
Pathogen resistance 48.15 10.83 8 269377 8108 29297034
Hospitalisation 48.12 10.83 235 269150 45753 29259389
Balanoposthitis 47.61 10.83 52 269333 950 29304192
Myelosuppression 47.56 10.83 26 269359 12201 29292941
Sepsis 47.56 10.83 965 268420 141717 29163425
Microalbuminuria 47.17 10.83 43 269342 625 29304517
Progressive multifocal leukoencephalopathy 46.68 10.83 11 269374 8708 29296434
Diabetic nephropathy 46.68 10.83 71 269314 1824 29303318
Arthralgia 46.31 10.83 945 268440 138672 29166470
Mucosal inflammation 46.23 10.83 141 269244 31454 29273688
Aspartate aminotransferase increased 46.19 10.83 336 269049 59389 29245753
Infection 45.01 10.83 464 268921 76287 29228855
Infective pulmonary exacerbation of cystic fibrosis 44.98 10.83 3 269382 6233 29298909
Drug intolerance 44.62 10.83 258 269127 48121 29257021
Rheumatoid arthritis 44.58 10.83 147 269238 32005 29273137
Urine albumin/creatinine ratio abnormal 44.49 10.83 12 269373 0 29305142
Anion gap 43.62 10.83 43 269342 693 29304449
Immune reconstitution inflammatory syndrome 43.48 10.83 9 269376 7793 29297349
Psoriasis 43.43 10.83 467 268918 31760 29273382
Coronary artery disease 43.31 10.83 603 268782 43587 29261555
Cytomegalovirus viraemia 42.91 10.83 4 269381 6316 29298826
Haemophagocytic lymphohistiocytosis 42.84 10.83 21 269364 10483 29294659
Condition aggravated 42.83 10.83 1010 268375 145285 29159857
Therapeutic product effect decreased 42.69 10.83 132 269253 29319 29275823
Glycosylated haemoglobin abnormal 42.50 10.83 21 269364 97 29305045
Diabetic ketoacidotic hyperglycaemic coma 42.46 10.83 23 269362 133 29305009
Deep vein thrombosis 42.44 10.83 327 269058 57072 29248070
Obesity 42.17 10.83 190 269195 9673 29295469
Rash 41.34 10.83 1366 268019 188453 29116689
Interstitial lung disease 41.20 10.83 332 269053 57386 29247756
Pseudomonas infection 40.89 10.83 24 269361 10828 29294314
Septic shock 40.56 10.83 369 269016 62191 29242951
Adenocarcinoma pancreas 40.54 10.83 53 269332 1178 29303964
Hypoxia 40.38 10.83 259 269126 47120 29258022
Drug hypersensitivity 40.33 10.83 413 268972 67993 29237149
Diabetic foot infection 40.25 10.83 38 269347 579 29304563
Therapy non-responder 39.71 10.83 146 269239 30765 29274377
Product use issue 39.49 10.83 290 269095 51154 29253988
Thirst 38.96 10.83 139 269246 6352 29298790
Clostridium difficile infection 38.95 10.83 54 269331 16087 29289055
Pancreatic neoplasm 38.84 10.83 43 269342 798 29304344
Post transplant lymphoproliferative disorder 38.60 10.83 3 269382 5490 29299652
Coma 38.53 10.83 538 268847 38912 29266230
Synovitis 38.39 10.83 26 269359 10864 29294278
Epstein-Barr virus infection 38.30 10.83 7 269378 6622 29298520
Blood ketone body increased 38.11 10.83 30 269355 352 29304790
Renal tubular necrosis 38.07 10.83 242 269143 14073 29291069
Genital infection fungal 37.22 10.83 22 269363 154 29304988
Haemodynamic instability 37.16 10.83 159 269226 7914 29297228
Osmolar gap increased 37.08 10.83 10 269375 0 29305142
Blood bicarbonate decreased 37.01 10.83 71 269314 2211 29302931
Exposure during pregnancy 36.59 10.83 16 269369 8538 29296604
Drug interaction 36.35 10.83 2170 267215 195215 29109927
Depression 36.30 10.83 551 268834 84596 29220546
Drug reaction with eosinophilia and systemic symptoms 36.10 10.83 132 269253 27860 29277282
Neoplasm progression 35.89 10.83 72 269313 18540 29286602
Anaemia 35.50 10.83 1483 267902 199468 29105674
C-reactive protein abnormal 35.48 10.83 8 269377 6528 29298614
Neurotoxicity 35.15 10.83 49 269336 14564 29290578
Staphylococcal infection 35.06 10.83 142 269243 29098 29276044
Obstructive pancreatitis 35.00 10.83 30 269355 400 29304742
Foetal exposure during pregnancy 34.88 10.83 174 269211 33693 29271449
Osmolar gap 34.82 10.83 13 269372 24 29305118
Haemorrhage 34.63 10.83 254 269131 44818 29260324
Glycosylated haemoglobin decreased 34.35 10.83 27 269358 316 29304826
Diabetic ketosis 33.83 10.83 17 269368 82 29305060
Hyperglycaemic hyperosmolar nonketotic syndrome 33.59 10.83 45 269340 1025 29304117
Polydipsia 32.78 10.83 87 269298 3378 29301764
Vitamin B12 decreased 32.65 10.83 44 269341 1008 29304134
Hallucination 32.45 10.83 256 269129 44456 29260686
Urine ketone body 32.41 10.83 14 269371 44 29305098
Haemoptysis 32.02 10.83 156 269229 30394 29274748
Musculoskeletal stiffness 31.79 10.83 205 269180 37253 29267889
Insomnia 31.76 10.83 593 268792 88168 29216974
Naevus flammeus 31.36 10.83 19 269366 140 29305002
Haematotoxicity 31.18 10.83 11 269374 6688 29298454
Blood cholesterol 30.87 10.83 20 269365 168 29304974
Glycosuria 30.72 10.83 45 269340 1117 29304025
Lumbosacral radiculoplexus neuropathy 30.59 10.83 12 269373 27 29305115
Blood ketone body 30.40 10.83 15 269370 69 29305073
Abdominal pain 30.20 10.83 1515 267870 133842 29171300
Pancreatic neuroendocrine tumour 30.09 10.83 21 269364 202 29304940
Plasma cell myeloma 30.05 10.83 206 269179 36909 29268233
Diabetic foot 30.04 10.83 64 269321 2152 29302990
Hepatic steatosis 30.00 10.83 236 269149 14710 29290432
Osteonecrosis 29.93 10.83 48 269337 13471 29291671
Cardiovascular disorder 29.55 10.83 160 269225 8775 29296367
Vitamin B1 deficiency 29.18 10.83 22 269363 241 29304901
Aplastic anaemia 29.17 10.83 16 269369 7494 29297648
Chills 29.16 10.83 465 268920 70835 29234307
Tongue oedema 29.07 10.83 69 269316 2497 29302645
Haemoglobin decreased 29.03 10.83 758 268627 107617 29197525
Acute myocardial infarction 28.87 10.83 610 268775 47828 29257314
Sinusitis 28.64 10.83 189 269196 34161 29270981
No adverse event 28.52 10.83 74 269311 17404 29287738
Syncope 28.33 10.83 955 268430 80416 29224726
Cytopenia 28.03 10.83 29 269356 9830 29295312
Antipsychotic drug level decreased 27.98 10.83 37 269348 832 29304310
Cholelithiasis 27.72 10.83 276 269109 18396 29286746
Bladder transitional cell carcinoma 27.69 10.83 66 269319 2395 29302747
Glucose urine present 27.65 10.83 39 269346 934 29304208
Dystonia 27.35 10.83 29 269356 9720 29295422
Acute coronary syndrome 27.20 10.83 199 269186 12126 29293016
5-hydroxyindolacetic acid in urine increased 27.06 10.83 20 269365 212 29304930
Myelodysplastic syndrome 27.05 10.83 78 269307 17716 29287426
Cytokine release syndrome 26.82 10.83 49 269336 13070 29292072
Blood mercury abnormal 26.78 10.83 19 269366 188 29304954
Joint swelling 26.69 10.83 306 269079 49324 29255818
Disseminated intravascular coagulation 26.57 10.83 93 269292 19887 29285255
Diabetic eye disease 26.41 10.83 12 269373 44 29305098
Anaemia megaloblastic 26.32 10.83 18 269367 167 29304975
Osteonecrosis of jaw 26.11 10.83 71 269314 16439 29288703
Colitis 26.02 10.83 172 269213 31076 29274066
Alveolar capillary dysplasia 25.95 10.83 7 269378 0 29305142
Diabetic macroangiopathy 25.82 10.83 8 269377 5 29305137
Acquired phimosis 25.66 10.83 13 269372 64 29305078
Starvation ketoacidosis 25.60 10.83 11 269374 34 29305108
Clostridium difficile colitis 25.57 10.83 51 269334 13161 29291981
Pulmonary haemorrhage 25.54 10.83 28 269357 9242 29295900
Therapeutic response decreased 25.42 10.83 127 269258 24584 29280558
Anaemia vitamin B12 deficiency 25.31 10.83 21 269364 267 29304875
Pneumothorax 25.15 10.83 68 269317 15774 29289368
Multiple-drug resistance 25.11 10.83 3 269382 3897 29301245
Epistaxis 25.07 10.83 326 269059 51378 29253764
Peritonitis 24.78 10.83 62 269323 14762 29290380
Nausea 24.61 10.83 3001 266384 286254 29018888
Therapeutic product effect incomplete 24.54 10.83 234 269151 39071 29266071
Bradyarrhythmia 24.27 10.83 55 269330 1930 29303212
Pancreatic pseudocyst 24.13 10.83 33 269352 767 29304375
Lymphocyte count decreased 24.11 10.83 92 269293 19179 29285963
Coma scale abnormal 24.08 10.83 78 269307 3391 29301751
Cardiac failure 24.02 10.83 916 268469 78371 29226771
Hyperoxaluria 23.96 10.83 15 269370 118 29305024
Stevens-Johnson syndrome 23.86 10.83 74 269311 16423 29288719
Arthropathy 23.80 10.83 108 269277 21446 29283696
Rectal haemorrhage 23.61 10.83 201 269184 34348 29270794
Clear cell renal cell carcinoma 23.56 10.83 37 269348 978 29304164
Neuropathic arthropathy 23.52 10.83 16 269369 147 29304995
Suicidal ideation 23.27 10.83 203 269182 34513 29270629
Burkholderia pseudomallei infection 23.25 10.83 10 269375 31 29305111
Pollakiuria 23.19 10.83 246 269139 16670 29288472
Osteoporosis 23.13 10.83 39 269346 10730 29294412
Pleural effusion 23.13 10.83 489 268896 71419 29233723
Cardiogenic shock 23.09 10.83 272 269113 18918 29286224
Expired product administered 23.06 10.83 67 269318 2744 29302398
Unevaluable event 23.03 10.83 168 269217 29683 29275459
Needle issue 22.93 10.83 94 269291 4589 29300553
Substance abuse 22.88 10.83 17 269368 6770 29298372
Dysphagia 22.86 10.83 357 269028 54569 29250573
Low density lipoprotein abnormal 22.81 10.83 19 269366 243 29304899
Cornea verticillata 22.79 10.83 10 269375 33 29305109
Neuropathy vitamin B12 deficiency 22.72 10.83 9 269376 21 29305121
Abdominal discomfort 22.61 10.83 584 268801 47319 29257823
Tumour lysis syndrome 22.49 10.83 59 269326 13825 29291317
Ascites 22.44 10.83 219 269166 36400 29268742
Schizophrenia 22.01 10.83 118 269267 6447 29298695
Renal impairment 21.94 10.83 928 268457 80405 29224737
Immunosuppressant drug level increased 21.88 10.83 8 269377 4757 29300385
Psychotic disorder 21.87 10.83 103 269282 20251 29284891
Product monitoring error 21.65 10.83 63 269322 2582 29302560
Cerebrovascular accident 21.53 10.83 881 268504 76030 29229112
Flushing 21.50 10.83 165 269220 28827 29276315
Type V hyperlipidaemia 21.40 10.83 29 269356 668 29304474
Dizziness 21.28 10.83 2005 267380 187679 29117463
Ileus 21.26 10.83 64 269321 14338 29290804
Acute myeloid leukaemia 21.20 10.83 78 269307 16435 29288707
Actinic elastosis 21.16 10.83 10 269375 41 29305101
Genital candidiasis 21.11 10.83 11 269374 58 29305084
Staphylococcal bacteraemia 21.07 10.83 20 269365 7059 29298083
Thrombotic microangiopathy 20.99 10.83 29 269356 8652 29296490
Tongue disorder 20.92 10.83 8 269377 4628 29300514
Herpes zoster 20.91 10.83 174 269211 29878 29275264
Albumin urine present 20.65 10.83 21 269364 352 29304790
Enterococcal infection 20.62 10.83 27 269358 8241 29296901
Vitreous haemorrhage 20.54 10.83 52 269333 1961 29303181
Drug withdrawal syndrome 20.52 10.83 89 269296 17895 29287247
Neoplasm malignant 20.41 10.83 82 269303 16843 29288299
Malaise 20.36 10.83 1703 267682 157899 29147243
Large for dates baby 20.13 10.83 32 269353 855 29304287
Lymphopenia 20.07 10.83 60 269325 13473 29291669
Food aversion 20.01 10.83 20 269365 328 29304814
Basilar artery thrombosis 19.99 10.83 15 269370 163 29304979
Productive cough 19.98 10.83 185 269200 31074 29274068
Haematuria 19.93 10.83 535 268850 43604 29261538
Medication error 19.80 10.83 287 269098 20924 29284218
Status epilepticus 19.76 10.83 43 269342 10751 29294391
Angina pectoris 19.71 10.83 360 269025 27490 29277652
Balanitis candida 19.70 10.83 13 269372 113 29305029
Hepatojugular reflux 19.64 10.83 23 269362 455 29304687
Renal oncocytoma 19.60 10.83 9 269376 34 29305108
Body temperature decreased 19.57 10.83 165 269220 10499 29294643
Intestinal perforation 19.56 10.83 27 269358 8059 29297083
Aplasia pure red cell 19.50 10.83 13 269372 5478 29299664
Tenosynovitis 19.42 10.83 5 269380 3728 29301414
Abnormal behaviour 19.40 10.83 127 269258 23000 29282142
Epilepsy 19.38 10.83 94 269291 18338 29286804
Device related infection 19.33 10.83 75 269310 15561 29289581
Product commingling 19.29 10.83 8 269377 22 29305120
Pneumonia aspiration 19.17 10.83 228 269157 36509 29268633
Respiratory arrest 19.16 10.83 147 269238 25686 29279456
Nipple inflammation 19.15 10.83 10 269375 53 29305089
Drug level above therapeutic 19.12 10.83 70 269315 3240 29301902
Bacteraemia 19.11 10.83 80 269305 16243 29288899
Cytomegalovirus test positive 18.97 10.83 4 269381 3419 29301723
Leukocytosis 18.92 10.83 284 269101 20858 29284284
Retroperitoneal fibrosis 18.87 10.83 18 269367 278 29304864
Tremor 18.72 10.83 518 268867 73020 29232122
Appendicitis 18.66 10.83 32 269353 8747 29296395
Gangrene 18.59 10.83 82 269303 4136 29301006
Abdominal pain upper 18.55 10.83 705 268680 60288 29244854
Birt-Hogg-Dube syndrome 18.54 10.83 5 269380 0 29305142
Headache 18.45 10.83 1350 268035 172657 29132485
pH body fluid abnormal 18.39 10.83 7 269378 14 29305128
Blood pressure fluctuation 18.38 10.83 106 269279 19788 29285354
Urine output increased 18.32 10.83 34 269351 1032 29304110
Drug level below therapeutic 18.25 10.83 8 269377 4263 29300879
Respiratory failure 18.14 10.83 712 268673 96419 29208723
Palmar-plantar erythrodysaesthesia syndrome 18.12 10.83 71 269314 14688 29290454
Conjunctivitis 18.08 10.83 28 269357 7970 29297172
Plasmapheresis 18.07 10.83 18 269367 294 29304848
Oxygen saturation decreased 18.05 10.83 294 269091 44643 29260499
Bronchitis 18.04 10.83 232 269153 36636 29268506
Gastroenteritis 18.01 10.83 185 269200 12431 29292711
Glomerular filtration rate increased 17.99 10.83 15 269370 192 29304950
Nasopharyngitis 17.96 10.83 410 268975 59255 29245887
Pneumonitis 17.91 10.83 166 269219 27878 29277264
Pulmonary alveolar haemorrhage 17.88 10.83 19 269366 6361 29298781
Cystitis haemorrhagic 17.83 10.83 11 269374 4831 29300311
Erythromelalgia 17.81 10.83 9 269376 44 29305098
Pain in extremity 17.80 10.83 823 268562 109610 29195532
Blood triglycerides increased 17.76 10.83 187 269198 12647 29292495
Anaphylactic reaction 17.70 10.83 163 269222 27410 29277732
Premature baby 17.66 10.83 89 269296 17191 29287951
Stenosis 17.64 10.83 33 269352 1008 29304134
Brain natriuretic peptide abnormal 17.59 10.83 18 269367 304 29304838
Cytomegalovirus chorioretinitis 17.50 10.83 4 269381 3234 29301908
Hepatic enzyme decreased 17.50 10.83 9 269376 46 29305096
Restlessness 17.39 10.83 124 269261 22021 29283121
Ischaemic cardiomyopathy 17.34 10.83 99 269286 5539 29299603
Malnutrition 17.34 10.83 47 269338 10894 29294248
Diabetic foetopathy 17.32 10.83 15 269370 203 29304939
Hypoalbuminaemia 17.30 10.83 43 269342 10262 29294880
Liver palpable 17.29 10.83 17 269368 273 29304869
Pain 17.23 10.83 1336 268049 170096 29135046
Mydriasis 17.19 10.83 18 269367 6067 29299075
Cardiotoxicity 17.16 10.83 11 269374 4733 29300409
Migraine 17.11 10.83 57 269328 12373 29292769
Amylase increased 17.09 10.83 94 269291 5186 29299956
Left ventricular dysfunction 17.01 10.83 139 269246 8763 29296379
Upper respiratory tract infection 16.99 10.83 163 269222 27186 29277956
Hypovolaemic shock 16.99 10.83 104 269281 5968 29299174
Blood pressure systolic increased 16.96 10.83 231 269154 16614 29288528
Autoimmune pancreatitis 16.95 10.83 17 269368 280 29304862
Serotonin syndrome 16.89 10.83 92 269293 17420 29287722
Atrial enlargement 16.87 10.83 18 269367 320 29304822
Akathisia 16.83 10.83 22 269363 6720 29298422
Haematocrit decreased 16.77 10.83 176 269209 28846 29276296
Pericardial disease 16.73 10.83 19 269366 363 29304779
Wheezing 16.70 10.83 208 269177 33032 29272110
Mucosal dryness 16.67 10.83 32 269353 997 29304145
Liver disorder 16.56 10.83 167 269218 27582 29277560
Echocardiogram abnormal 16.52 10.83 29 269356 842 29304300
Hepatic vein dilatation 16.51 10.83 15 269370 217 29304925
Klebsiella infection 16.36 10.83 26 269359 7323 29297819
Product substitution issue 16.35 10.83 141 269244 9031 29296111
Hyperventilation 16.30 10.83 53 269332 2309 29302833
Therapy partial responder 16.30 10.83 14 269371 5185 29299957
Angioedema 16.22 10.83 393 268992 31522 29273620
Leukoencephalopathy 16.19 10.83 7 269378 3760 29301382
Hyperlipasaemia 16.09 10.83 21 269364 466 29304676
Metabolic syndrome 16.03 10.83 39 269346 1434 29303708
Prerenal failure 16.02 10.83 44 269341 1744 29303398
Intercapillary glomerulosclerosis 16.01 10.83 8 269377 38 29305104
Enthesopathy 16.01 10.83 7 269378 3736 29301406
Herbal interaction 15.72 10.83 17 269368 307 29304835
Pancreatitis haemorrhagic 15.72 10.83 17 269368 307 29304835
Anion gap abnormal 15.66 10.83 12 269373 135 29305007
Scrotal cyst 15.64 10.83 5 269380 4 29305138
Injection site mass 15.62 10.83 94 269291 5361 29299781
Encephalitis toxic 15.60 10.83 16 269369 271 29304871
Pancreaticoduodenectomy 15.58 10.83 9 269376 60 29305082
Hypoglycaemic encephalopathy 15.55 10.83 16 269369 272 29304870
Pulmonary toxicity 15.53 10.83 13 269372 4877 29300265
Brain oedema 15.51 10.83 58 269327 12162 29292980
Fixed eruption 15.48 10.83 34 269351 1168 29303974
Sopor 15.45 10.83 160 269225 10774 29294368
Febrile bone marrow aplasia 15.44 10.83 27 269358 7324 29297818
Product appearance confusion 15.34 10.83 7 269378 26 29305116
Acute lung injury 15.27 10.83 36 269349 1297 29303845
Hypoglycaemic unconsciousness 15.25 10.83 26 269359 737 29304405
Leukaemoid reaction 15.24 10.83 10 269375 86 29305056
Insulin C-peptide decreased 15.23 10.83 8 269377 43 29305099
Renal artery thrombosis 15.23 10.83 16 269369 279 29304863
Blood cholesterol abnormal 15.23 10.83 38 269347 1420 29303722
Drug ineffective for unapproved indication 15.23 10.83 72 269313 14142 29291000
Tendonitis 15.17 10.83 31 269354 7930 29297212
Disease recurrence 15.13 10.83 84 269301 15830 29289312
Pulmonary valve disease 15.10 10.83 16 269369 282 29304860
Lymphoma 14.99 10.83 43 269342 9785 29295357
Escherichia infection 14.99 10.83 24 269361 6740 29298402
Kussmaul respiration 14.96 10.83 10 269375 89 29305053
Fibrillary glomerulonephritis 14.94 10.83 8 269377 45 29305097
Skinfold measurement 14.83 10.83 4 269381 0 29305142
Atrioventricular node dysfunction 14.83 10.83 4 269381 0 29305142
Blood insulin decreased 14.83 10.83 4 269381 0 29305142
Atrioventricular block first degree 14.81 10.83 91 269294 5228 29299914
Central obesity 14.78 10.83 20 269365 460 29304682
Product complaint 14.76 10.83 92 269293 5313 29299829
Bradycardia 14.70 10.83 735 268650 64894 29240248
Hypersensitivity 14.69 10.83 368 269017 52535 29252607
Dermatitis acneiform 14.67 10.83 17 269368 5474 29299668
Rhabdomyolysis 14.67 10.83 686 268699 60122 29245020
Hyperammonaemia 14.63 10.83 18 269367 5645 29299497
Spondylolysis 14.53 10.83 8 269377 48 29305094
Therapeutic drug monitoring analysis not performed 14.46 10.83 20 269365 470 29304672
Pulmonary tuberculosis 14.30 10.83 11 269374 4304 29300838
Pulmonary embolism 14.29 10.83 561 268824 75973 29229169
Oedematous pancreatitis 14.27 10.83 19 269366 430 29304712
Coma acidotic 14.23 10.83 5 269380 7 29305135
Atrioventricular block complete 14.20 10.83 123 269262 7888 29297254
Irritability 14.20 10.83 131 269254 22021 29283121
Peritonitis bacterial 14.15 10.83 19 269366 5737 29299405
Transaminases increased 14.10 10.83 135 269250 22527 29282615
Hypogammaglobulinaemia 14.01 10.83 20 269365 5887 29299255
High density lipoprotein decreased 13.96 10.83 59 269326 2920 29302222
Gingival hypertrophy 13.96 10.83 40 269345 1625 29303517
Product solubility abnormal 13.95 10.83 19 269366 440 29304702
Respiratory syncytial virus infection 13.91 10.83 8 269377 3651 29301491
Lung disorder 13.79 10.83 194 269191 30168 29274974
Chronic pigmented purpura 13.77 10.83 10 269375 103 29305039
Pernicious anaemia 13.76 10.83 9 269376 77 29305065
Anhedonia 13.75 10.83 28 269357 7172 29297970
Thrombosis 13.75 10.83 293 269092 42752 29262390
C-reactive protein increased 13.65 10.83 303 269082 43960 29261182
Bacterial infection 13.63 10.83 66 269319 12882 29292260
Weight increased 13.52 10.83 840 268545 75827 29229315
Torsade de pointes 13.51 10.83 25 269360 6636 29298506
Orbital oedema 13.51 10.83 11 269374 136 29305006
Inflammation 13.47 10.83 137 269248 22591 29282551
Hypoparathyroidism 13.47 10.83 19 269366 455 29304687
Nipple disorder 13.47 10.83 12 269373 169 29304973
Dyslipidaemia 13.45 10.83 98 269287 5963 29299179
Pneumatosis intestinalis 13.44 10.83 6 269379 3163 29301979
Vitamin B1 decreased 13.43 10.83 14 269371 242 29304900
Intentional self-injury 13.42 10.83 63 269322 12398 29292744
Graft versus host disease in skin 13.41 10.83 7 269378 3372 29301770
Sedation 13.40 10.83 98 269287 17307 29287835
Emotional distress 13.40 10.83 73 269312 13822 29291320
Staphylococcal sepsis 13.35 10.83 39 269346 8823 29296319
Myoclonus 13.35 10.83 69 269316 13240 29291902
Abnormal loss of weight 13.35 10.83 67 269318 3567 29301575
Subdural hygroma 13.32 10.83 15 269370 284 29304858
Hypoaesthesia eye 13.20 10.83 6 269379 22 29305120
Oscillopsia 13.13 10.83 7 269378 39 29305103
Pyonephrosis 13.09 10.83 8 269377 60 29305082
Drug dose titration not performed 13.07 10.83 14 269371 250 29304892
Choluria 13.06 10.83 11 269374 143 29304999
Alopecia 13.05 10.83 111 269274 18973 29286169
Hyperdynamic left ventricle 13.01 10.83 10 269375 113 29305029
Coma uraemic 12.99 10.83 7 269378 40 29305102
Blood creatinine increased 12.97 10.83 921 268464 84181 29220961
Tinnitus 12.97 10.83 86 269299 15528 29289614
Small intestinal obstruction 12.94 10.83 68 269317 12993 29292149
Exercise tolerance decreased 12.82 10.83 74 269311 4157 29300985
Urosepsis 12.79 10.83 152 269233 10594 29294548
Pneumonia bacterial 12.75 10.83 43 269342 9300 29295842
Tachypnoea 12.74 10.83 201 269184 14914 29290228
Multiple sclerosis relapse 12.73 10.83 57 269328 11362 29293780
Hemiparaesthesia 12.72 10.83 7 269378 42 29305100
Bradypnoea 12.68 10.83 3 269382 2368 29302774
Cerebellar ischaemia 12.66 10.83 10 269375 118 29305024
Diabetic gangrene 12.65 10.83 12 269373 184 29304958
Haematochezia 12.63 10.83 249 269136 36734 29268408
Benign neoplasm of adrenal gland 12.62 10.83 4 269381 3 29305139
Hepatobiliary scan abnormal 12.62 10.83 4 269381 3 29305139
Essential hypertension 12.62 10.83 50 269335 2403 29302739
Pancreatic duct obstruction 12.62 10.83 4 269381 3 29305139
Macular oedema 12.56 10.83 50 269335 2408 29302734
Mouth haemorrhage 12.56 10.83 15 269370 4765 29300377
Pseudomembranous colitis 12.55 10.83 4 269381 2593 29302549
Ejection fraction decreased 12.55 10.83 210 269175 15768 29289374
Lichenification 12.47 10.83 14 269371 264 29304878
Cardiac septal hypertrophy 12.47 10.83 14 269371 264 29304878
Bladder papilloma 12.44 10.83 6 269379 26 29305116
Vasoplegia syndrome 12.42 10.83 36 269349 1472 29303670
Ventricular enlargement 12.31 10.83 18 269367 446 29304696
Neonatal respiratory distress syndrome 12.26 10.83 10 269375 3800 29301342
Vascular resistance systemic decreased 12.21 10.83 9 269376 95 29305047
Red blood cell count decreased 12.19 10.83 162 269223 25440 29279702
Rales 12.13 10.83 113 269272 7397 29297745
Bacterial sepsis 12.10 10.83 15 269370 4688 29300454
Blood albumin decreased 12.09 10.83 60 269325 11635 29293507
Bone erosion 12.07 10.83 5 269380 2755 29302387
Lip swelling 12.01 10.83 169 269216 12241 29292901
Finger amputation 12.01 10.83 11 269374 161 29304981
Lichen sclerosus 11.99 10.83 5 269380 14 29305128
Cardiac discomfort 11.96 10.83 18 269367 458 29304684
Eosinophilic colitis 11.95 10.83 12 269373 198 29304944
Blood bilirubin increased 11.93 10.83 227 269158 33666 29271476
Post-traumatic amnestic disorder 11.84 10.83 7 269378 49 29305093
Endometriosis male 11.74 10.83 5 269380 15 29305127
Blood alkaline phosphatase increased 11.69 10.83 185 269200 28221 29276921
Dermatosis 11.64 10.83 14 269371 285 29304857
Diabetic vascular disorder 11.61 10.83 6 269379 31 29305111
Viral infection 11.59 10.83 83 269302 14727 29290415
Base excess decreased 11.57 10.83 12 269373 206 29304936
Bundle branch block left 11.53 10.83 85 269300 5192 29299950
Venous occlusion 11.52 10.83 15 269370 332 29304810
Alcoholic ketoacidosis 11.51 10.83 5 269380 16 29305126
Generalised tonic-clonic seizure 11.50 10.83 115 269270 19024 29286118
Hepatic haematoma 11.47 10.83 16 269369 379 29304763
Penile infection 11.46 10.83 6 269379 32 29305110
Hemianopia homonymous 11.42 10.83 22 269363 687 29304455
Methaemoglobinaemia 11.42 10.83 5 269380 2666 29302476
Squamous cell carcinoma of skin 11.41 10.83 46 269339 9440 29295702
Pancreatitis necrotising 11.41 10.83 47 269338 2300 29302842
Lip oedema 11.40 10.83 45 269340 2159 29302983
Large intestine perforation 11.36 10.83 32 269353 7324 29297818
Blood lactate dehydrogenase increased 11.30 10.83 116 269269 19093 29286049
Body mass index increased 11.25 10.83 24 269361 808 29304334
Cardiovascular insufficiency 11.23 10.83 33 269352 1360 29303782
Base excess negative 11.22 10.83 4 269381 6 29305136
Intraductal papillary-mucinous carcinoma of pancreas 11.22 10.83 4 269381 6 29305136
Diabetic complication 11.21 10.83 21 269364 642 29304500
Virologic failure 11.15 10.83 6 269379 2841 29302301
Pure white cell aplasia 11.12 10.83 3 269382 0 29305142
Dawn phenomenon 11.12 10.83 3 269382 0 29305142
Thyroid calcification 11.12 10.83 3 269382 0 29305142
Diabetic encephalopathy 11.12 10.83 3 269382 0 29305142
Genital tract inflammation 11.12 10.83 3 269382 0 29305142
Benign neoplasm of testis 11.12 10.83 3 269382 0 29305142
Thyroid C-cell hyperplasia 11.12 10.83 3 269382 0 29305142
Base excess 11.12 10.83 3 269382 0 29305142
Myasthenic syndrome 11.10 10.83 16 269369 391 29304751
Erythema 11.09 10.83 569 268816 75037 29230105
Metastases to the mediastinum 11.08 10.83 12 269373 217 29304925
Product label issue 11.08 10.83 12 269373 217 29304925
Foetal malnutrition 11.08 10.83 7 269378 56 29305086
Back pain 11.07 10.83 792 268593 101492 29203650
Swollen tongue 11.06 10.83 165 269220 12101 29293041
Serum ferritin abnormal 10.95 10.83 12 269373 220 29304922
Heat stroke 10.91 10.83 25 269360 884 29304258
Electrocardiogram QT interval 10.90 10.83 6 269379 36 29305106
Body temperature increased 10.87 10.83 82 269303 14383 29290759
Neuropathic ulcer 10.87 10.83 5 269380 19 29305123
Arthropod sting 10.85 10.83 14 269371 307 29304835

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 22134.48 10.40 10324 483641 51086 63953681
Acute kidney injury 5247.62 10.40 10969 482996 438271 63566496
Hypoglycaemia 4563.17 10.40 4453 489512 85439 63919328
Metabolic acidosis 3524.82 10.40 3475 490490 67483 63937284
Diabetic ketoacidosis 3059.60 10.40 2220 491745 27625 63977142
Blood glucose increased 2058.45 10.40 3105 490860 94968 63909799
Hyperkalaemia 1582.27 10.40 2804 491161 98325 63906442
Euglycaemic diabetic ketoacidosis 1414.88 10.40 733 493232 4677 64000090
Diabetes mellitus inadequate control 1278.66 10.40 1160 492805 20161 63984606
Ketoacidosis 1227.94 10.40 724 493241 6139 63998628
Glycosylated haemoglobin increased 1202.76 10.40 991 492974 15028 63989739
Hyperglycaemia 978.21 10.40 1710 492255 59258 63945509
Shock 713.86 10.40 1148 492817 37092 63967675
Hypoglycaemic coma 679.58 10.40 418 493547 3856 64000911
Hyperlactacidaemia 670.67 10.40 434 493531 4410 64000357
Drug ineffective 659.26 10.40 3765 490200 836482 63168285
Pancreatitis acute 647.41 10.40 1171 492794 41684 63963083
Pancreatitis 613.99 10.40 1389 492576 58218 63946549
Pemphigoid 579.85 10.40 601 493364 12385 63992382
Off label use 519.52 10.40 2791 491174 630015 63374752
Diabetic metabolic decompensation 472.87 10.40 282 493683 2446 64002321
Anuria 459.13 10.40 643 493322 18321 63986446
Renal failure 458.65 10.40 2663 491302 179025 63825742
Synovitis 442.70 10.40 107 493858 98983 63905784
Blood lactic acid increased 422.91 10.40 458 493507 9943 63994824
Drug intolerance 422.53 10.40 490 493475 187502 63817265
Blood glucose decreased 419.00 10.40 685 493280 22438 63982329
Systemic lupus erythematosus 418.45 10.40 51 493914 77561 63927206
Infusion related reaction 408.44 10.40 394 493571 164073 63840694
Blood glucose abnormal 398.83 10.40 413 493552 8500 63996267
Treatment failure 374.99 10.40 214 493751 116602 63888165
Hand deformity 354.24 10.40 35 493930 62736 63942031
Arthropathy 340.34 10.40 257 493708 120710 63884057
Vitamin B12 deficiency 336.42 10.40 302 493663 5170 63999597
Febrile neutropenia 334.36 10.40 577 493388 187080 63817687
Vomiting 330.22 10.40 5988 487977 545129 63459638
Joint swelling 329.38 10.40 725 493240 214657 63790110
Toxicity to various agents 322.67 10.40 4223 489742 359290 63645477
Pemphigus 312.65 10.40 46 493919 60655 63944112
Drug level increased 311.84 10.40 760 493205 33436 63971331
Dehydration 311.58 10.40 2774 491191 213989 63790778
Intentional overdose 306.10 10.40 1433 492532 88511 63916256
Glossodynia 304.81 10.40 62 493903 64634 63940133
Pancreatic carcinoma 302.15 10.40 385 493580 9988 63994779
Pyrexia 295.25 10.40 2796 491169 555848 63448919
Haemodialysis 294.77 10.40 495 493470 16582 63988185
Diarrhoea 288.67 10.40 7404 486561 715300 63289467
Drug abuse 285.67 10.40 356 493609 132018 63872749
Rheumatoid arthritis 285.55 10.40 513 493452 163781 63840986
Completed suicide 279.13 10.40 2785 491180 221629 63783138
Neutropenia 271.15 10.40 934 493031 238690 63766077
Hypothermia 270.32 10.40 519 493446 19337 63985430
Continuous haemodiafiltration 258.42 10.40 170 493795 1780 64002987
Anion gap increased 253.21 10.40 200 493765 2844 64001923
Therapeutic product effect decreased 252.27 10.40 307 493658 115044 63889723
Rash 242.88 10.40 2293 491672 456256 63548511
Acidosis 240.86 10.40 464 493501 17331 63987436
Rheumatoid factor positive 238.86 10.40 6 493959 34932 63969835
Blood glucose fluctuation 234.74 10.40 258 493707 5697 63999070
Drug hypersensitivity 234.67 10.40 980 492985 236835 63767932
Arthralgia 231.02 10.40 2219 491746 440041 63564726
Pericarditis 230.28 10.40 95 493870 62421 63942346
Hypersensitivity 228.83 10.40 756 493209 195696 63809071
Alopecia 222.25 10.40 597 493368 165093 63839674
Stomatitis 216.93 10.40 314 493651 109291 63895476
Infection 208.13 10.40 722 493243 184158 63820609
Duodenal ulcer perforation 201.54 10.40 17 493948 34608 63970159
Blood bicarbonate decreased 195.19 10.40 212 493753 4617 64000150
Contraindicated product administered 193.36 10.40 330 493635 107499 63897268
Drug interaction 193.18 10.40 3867 490098 358216 63646551
Hypomagnesaemia 186.18 10.40 670 493295 36706 63968061
Bladder cancer 183.96 10.40 314 493651 10660 63994107
Overdose 183.83 10.40 1950 492015 157616 63847151
Sinusitis 182.98 10.40 543 493422 145385 63859382
Product use in unapproved indication 182.85 10.40 714 493251 175904 63828863
Pain 176.65 10.40 3080 490885 550431 63454336
Musculoskeletal stiffness 175.91 10.40 430 493535 122776 63881991
Sleep disorder due to general medical condition, insomnia type 174.15 10.40 6 493959 26264 63978503
Product use issue 173.08 10.40 589 493376 151126 63853641
Folliculitis 171.72 10.40 16 493949 30061 63974706
Swelling 170.82 10.40 640 493325 159578 63845189
Helicobacter infection 170.16 10.40 42 493923 38320 63966447
Ketonuria 169.36 10.40 106 493859 1011 64003756
Cytomegalovirus infection 166.42 10.40 40 493925 37159 63967608
Weight decreased 162.20 10.40 3081 490884 282658 63722109
Pneumonia 161.31 10.40 3169 490796 556407 63448360
Wound 159.42 10.40 211 493754 76266 63928501
Muscle injury 153.81 10.40 13 493952 26424 63978343
Diabetic neuropathy 152.37 10.40 201 493764 5400 63999367
Polyuria 148.77 10.40 311 493654 12332 63992435
Rhabdomyolysis 145.28 10.40 1200 492765 90526 63914241
Irritable bowel syndrome 142.19 10.40 54 493911 37315 63967452
Diabetes mellitus 141.46 10.40 933 493032 65541 63939226
Blood pH decreased 140.40 10.40 171 493794 4231 64000536
Maternal exposure during pregnancy 138.95 10.40 332 493633 95552 63909215
Ketosis 138.40 10.40 88 493877 865 64003902
Immune-mediated myositis 138.03 10.40 134 493831 2544 64002223
Injection site nodule 136.17 10.40 145 493820 3085 64001682
White blood cell count decreased 135.59 10.40 684 493281 157153 63847614
Hypotension 130.57 10.40 3830 490135 377144 63627623
C-reactive protein abnormal 130.40 10.40 31 493934 29016 63975751
Bone marrow failure 129.60 10.40 106 493859 47846 63956921
Thrombocytopenia 128.74 10.40 1095 492870 222706 63782061
Drug resistance 128.20 10.40 54 493911 35048 63969719
Urine ketone body present 128.14 10.40 142 493823 3165 64001602
Platelet count decreased 127.48 10.40 757 493208 166954 63837813
MELAS syndrome 126.21 10.40 47 493918 111 64004656
Base excess decreased 126.16 10.40 60 493905 309 64004458
Blood creatinine increased 121.54 10.40 1581 492384 134201 63870566
Myocardial infarction 119.32 10.40 1858 492107 163963 63840804
Death 112.77 10.40 2825 491140 479880 63524887
Suicide attempt 112.45 10.40 929 493036 70078 63934689
Acetonaemia 110.82 10.40 50 493915 223 64004544
Renal impairment 108.90 10.40 1543 492422 133474 63871293
Glomerular filtration rate decreased 105.36 10.40 360 493605 19212 63985555
Impaired healing 104.82 10.40 189 493776 60284 63944483
Tachypnoea 102.85 10.40 440 493525 26131 63978636
Contusion 100.65 10.40 489 493476 113476 63891291
Blood lactic acid 99.33 10.40 55 493910 408 64004359
Neurologic neglect syndrome 98.87 10.40 89 493876 1529 64003238
Leukopenia 98.61 10.40 419 493546 100823 63903944
Discomfort 98.43 10.40 305 493660 80573 63924194
Neutrophil count decreased 97.62 10.40 286 493679 76910 63927857
Distributive shock 95.11 10.40 93 493872 1782 64002985
Diabetic retinopathy 94.99 10.40 113 493852 2726 64002041
Hypocapnia 94.55 10.40 58 493907 532 64004235
Seizure 93.95 10.40 821 493144 166071 63838696
Renal tubular necrosis 93.32 10.40 376 493589 21734 63983033
Nasopharyngitis 92.91 10.40 1006 492959 195067 63809700
Pneumocystis jirovecii pneumonia 92.45 10.40 48 493917 27586 63977181
Haemodynamic instability 91.70 10.40 287 493678 14625 63990142
Macroangiopathy 91.08 10.40 36 493929 106 64004661
Transplant rejection 90.02 10.40 13 493952 17388 63987379
Malignant neoplasm progression 89.20 10.40 503 493462 112368 63892399
Carotid artery thrombosis 89.13 10.40 88 493877 1707 64003060
Graft versus host disease 88.70 10.40 4 493961 13809 63990958
Anaemia vitamin B12 deficiency 87.23 10.40 55 493910 532 64004235
Suspected suicide 87.19 10.40 200 493765 8454 63996313
Lipase increased 86.56 10.40 275 493690 14127 63990640
Hepatic steatosis 86.35 10.40 467 493498 30540 63974227
Condition aggravated 86.22 10.40 2182 491783 370244 63634523
Exposure during pregnancy 84.88 10.40 307 493658 77368 63927399
Disease progression 84.68 10.40 686 493279 140994 63863773
Blood ketone body increased 83.51 10.40 55 493910 577 64004190
Hemiplegia 83.42 10.40 251 493714 12517 63992250
Hepatic enzyme increased 83.36 10.40 617 493348 129326 63875441
Posterior reversible encephalopathy syndrome 82.68 10.40 36 493929 22910 63981857
Type 2 diabetes mellitus 82.64 10.40 494 493471 33526 63971241
Headache 82.04 10.40 3270 490695 526197 63478570
Myelosuppression 81.81 10.40 40 493925 23790 63980977
Diabetic nephropathy 81.26 10.40 101 493864 2553 64002214
Ill-defined disorder 79.69 10.40 134 493831 43918 63960849
Exposure via ingestion 79.20 10.40 138 493827 4764 64000003
Urine albumin/creatinine ratio abnormal 78.69 10.40 21 493944 3 64004764
Therapy non-responder 78.43 10.40 251 493714 65648 63939119
Product residue present 77.08 10.40 109 493856 3133 64001634
Bradycardia 76.92 10.40 1303 492662 116916 63887851
Microalbuminuria 76.65 10.40 59 493906 806 64003961
Drug level above therapeutic 75.71 10.40 165 493800 6736 63998031
Bronchopulmonary aspergillosis 73.58 10.40 27 493938 19058 63985709
Hypovolaemia 73.23 10.40 273 493692 15213 63989554
Migraine 73.02 10.40 241 493724 62436 63942331
Polydipsia 72.98 10.40 147 493818 5674 63999093
Personality disorder 72.72 10.40 130 493835 4581 64000186
Angioedema 72.27 10.40 758 493207 61063 63943704
Coma acidotic 72.07 10.40 30 493935 105 64004662
Psoriasis 71.90 10.40 853 493112 70850 63933917
Latent autoimmune diabetes in adults 71.75 10.40 26 493939 55 64004712
Abdominal discomfort 71.68 10.40 974 492991 181348 63823419
Acute myocardial infarction 71.51 10.40 833 493132 68885 63935882
Mucosal inflammation 71.30 10.40 243 493722 62341 63942426
Infective pulmonary exacerbation of cystic fibrosis 70.88 10.40 5 493960 11791 63992976
Hypoglycaemic encephalopathy 70.69 10.40 49 493916 563 64004204
Vasoplegia syndrome 70.23 10.40 96 493869 2671 64002096
Therapeutic product effect incomplete 69.94 10.40 484 493481 102998 63901769
Aspergillus infection 68.73 10.40 20 493945 16359 63988408
Neurotoxicity 67.54 10.40 66 493899 27338 63977429
Inflammation 67.50 10.40 264 493701 65036 63939731
Rheumatoid nodule 66.51 10.40 9 493956 12642 63992125
Arthritis 66.49 10.40 373 493592 83441 63921326
Haemophagocytic lymphohistiocytosis 66.07 10.40 26 493939 17583 63987184
Pathogen resistance 65.76 10.40 9 493956 12534 63992233
Tenosynovitis 65.71 10.40 7 493958 11826 63992941
Epstein-Barr virus infection 65.38 10.40 9 493956 12479 63992288
Hypovolaemic shock 65.37 10.40 200 493765 10066 63994701
Progressive multifocal leukoencephalopathy 65.06 10.40 29 493936 18203 63986564
Pancreatic carcinoma metastatic 64.30 10.40 104 493861 3374 64001393
Product odour abnormal 63.80 10.40 60 493905 1093 64003674
Blood potassium increased 63.58 10.40 378 493587 25602 63979165
Intentional product use issue 63.48 10.40 448 493517 94916 63909851
Postprandial hypoglycaemia 63.23 10.40 24 493941 61 64004706
Adjustment disorder 61.91 10.40 90 493875 2655 64002112
Anaemia megaloblastic 61.89 10.40 42 493923 465 64004302
Injection site erythema 61.79 10.40 305 493660 70495 63934272
Bone erosion 61.55 10.40 8 493957 11587 63993180
Haematotoxicity 61.48 10.40 12 493953 12884 63991883
Vitamin B12 decreased 61.21 10.40 89 493876 2626 64002141
Venoocclusive liver disease 60.89 10.40 4 493961 10011 63994756
Glycosylated haemoglobin abnormal 60.27 10.40 27 493938 118 64004649
Fatigue 60.19 10.40 4928 489037 743802 63260965
Hyperglycaemic hyperosmolar nonketotic syndrome 60.13 10.40 70 493895 1649 64003118
Cytomegalovirus viraemia 58.63 10.40 7 493958 10821 63993946
Immune reconstitution inflammatory syndrome 58.62 10.40 12 493953 12458 63992309
Therapeutic response decreased 58.52 10.40 204 493761 51984 63952783
Thirst 57.75 10.40 238 493727 13899 63990868
Diabetic ketoacidotic hyperglycaemic coma 57.44 10.40 30 493935 195 64004572
Hepatic function abnormal 57.32 10.40 275 493690 64038 63940729
Pancytopenia 56.89 10.40 764 493201 142545 63862222
PCO2 decreased 56.71 10.40 89 493876 2813 64001954
Herpes zoster 56.70 10.40 364 493601 78823 63925944
Osteonecrosis 56.68 10.40 80 493885 28149 63976618
C-reactive protein increased 56.48 10.40 460 493505 94449 63910318
Osmolar gap 56.42 10.40 26 493939 123 64004644
Osteoporosis 56.07 10.40 152 493813 41928 63962839
Abdominal pain 56.03 10.40 2927 491038 309448 63695319
Peripheral swelling 55.11 10.40 1201 492764 207952 63796815
Myocardial ischaemia 54.80 10.40 335 493630 22916 63981851
Post transplant lymphoproliferative disorder 54.69 10.40 5 493960 9539 63995228
Cholelithiasis 54.62 10.40 561 493404 44945 63959822
Cardiac arrest 54.29 10.40 1555 492410 152509 63852258
Diabetic ketosis 53.91 10.40 34 493931 329 64004438
Cytokine release syndrome 52.70 10.40 49 493916 20780 63983987
Adenocarcinoma pancreas 52.17 10.40 68 493897 1805 64002962
Nausea 52.12 10.40 6822 487143 778978 63225789
Clostridium difficile infection 51.74 10.40 126 493839 36037 63968730
Pancreatitis chronic 51.61 10.40 96 493869 3490 64001277
Osmolar gap increased 51.17 10.40 17 493948 24 64004743
Insulin resistance 51.07 10.40 52 493913 1048 64003719
Coronary artery disease 50.85 10.40 696 493269 59737 63945030
Toe amputation 50.75 10.40 94 493871 3406 64001361
Flushing 50.63 10.40 373 493592 78275 63926492
Acute coronary syndrome 50.54 10.40 286 493679 19024 63985743
Genital infection fungal 49.76 10.40 25 493940 148 64004619
Malaise 49.47 10.40 3597 490368 392650 63612117
Amylase increased 49.40 10.40 175 493790 9510 63995257
Oliguria 49.36 10.40 232 493733 14344 63990423
Cerebrovascular accident 49.12 10.40 1391 492574 136192 63868575
Toxic epidermal necrolysis 48.96 10.40 135 493830 37031 63967736
Mobility decreased 48.84 10.40 421 493544 85419 63919348
Hospitalisation 48.74 10.40 356 493609 74851 63929916
Injection site reaction 48.65 10.40 188 493777 46476 63958291
Device expulsion 48.60 10.40 54 493911 21082 63983685
Glycosuria 48.23 10.40 69 493896 2005 64002762
Multiple sclerosis relapse 48.03 10.40 158 493807 40977 63963790
Swollen joint count increased 46.96 10.40 3 493962 7686 63997081
Diabetic foot infection 46.67 10.40 41 493924 681 64004086
Glucose urine present 46.62 10.40 60 493905 1572 64003195
Neuropathy peripheral 46.47 10.40 627 493338 116898 63887869
Anhidrosis 46.18 10.40 26 493939 200 64004567
Gastroenteritis 46.10 10.40 387 493578 29324 63975443
Glycosylated haemoglobin decreased 46.00 10.40 38 493927 578 64004189
Pain in jaw 45.90 10.40 159 493806 40596 63964171
Enthesopathy 45.88 10.40 9 493956 9629 63995138
Red blood cell sedimentation rate increased 45.35 10.40 108 493857 31127 63973640
Naevus flammeus 44.91 10.40 19 493946 70 64004697
Anion gap 44.73 10.40 63 493902 1804 64002963
Drug dependence 44.63 10.40 120 493845 33192 63971575
Hip arthroplasty 44.39 10.40 59 493906 21292 63983475
Lymphocyte count decreased 44.36 10.40 161 493804 40538 63964229
Eating disorder 44.05 10.40 249 493716 16556 63988211
Circulatory collapse 43.95 10.40 423 493542 33309 63971458
Stevens-Johnson syndrome 43.20 10.40 127 493838 34122 63970645
Product prescribing error 42.90 10.40 436 493529 34833 63969934
Cardiovascular disorder 42.75 10.40 237 493728 15644 63989123
Blood ketone body 42.69 10.40 21 493944 118 64004649
Bladder transitional cell carcinoma 42.16 10.40 69 493896 2261 64002506
Atrioventricular block 41.99 10.40 193 493772 11822 63992945
Needle issue 41.81 10.40 161 493804 9111 63995656
Kussmaul respiration 41.72 10.40 30 493935 367 64004400
Pleural effusion 41.19 10.40 701 493264 125858 63878909
Thrombotic microangiopathy 41.17 10.40 40 493925 16615 63988152
Staphylococcal infection 41.02 10.40 224 493741 50454 63954313
Insulin C-peptide decreased 40.95 10.40 17 493948 59 64004708
Dialysis 40.65 10.40 245 493720 16675 63988092
Osteonecrosis of jaw 40.52 10.40 162 493803 39663 63965104
Accidental overdose 40.42 10.40 414 493551 33143 63971624
Base excess negative 40.13 10.40 13 493952 16 64004751
Pregnancy 40.06 10.40 61 493904 20804 63983963
Sopor 39.66 10.40 374 493591 29287 63975480
Rheumatic fever 39.64 10.40 11 493954 9283 63995484
Pancreatic neoplasm 39.40 10.40 51 493914 1344 64003423
Loss of personal independence in daily activities 39.17 10.40 360 493605 72094 63932673
Cardiac failure 38.65 10.40 1306 492659 131067 63873700
Lymphopenia 38.63 10.40 87 493878 25570 63979197
Basilar artery thrombosis 38.53 10.40 26 493939 285 64004482
Alanine aminotransferase increased 38.45 10.40 792 493173 138239 63866528
High density lipoprotein decreased 38.44 10.40 90 493875 3856 64000911
Clostridium difficile colitis 38.05 10.40 96 493869 27127 63977640
Interstitial lung disease 37.70 10.40 524 493441 97208 63907559
Oral herpes 37.69 10.40 70 493895 22082 63982685
Blister 37.67 10.40 417 493548 80550 63924217
Antipsychotic drug level decreased 37.38 10.40 41 493924 903 64003864
Unintentional medical device removal 37.35 10.40 4 493961 6730 63998037
Knee arthroplasty 37.13 10.40 96 493869 26903 63977864
Aspartate aminotransferase increased 36.59 10.40 671 493294 119117 63885650
Syncope 36.59 10.40 1516 492449 156119 63848648
Hypoglycaemic unconsciousness 36.49 10.40 44 493921 1077 64003690
Prerenal failure 36.45 10.40 78 493887 3144 64001623
Affect lability 36.44 10.40 151 493814 8839 63995928
Dystonia 36.37 10.40 55 493910 18810 63985957
Confusional state 36.29 10.40 2392 491573 258752 63746015
Mouth ulceration 36.25 10.40 127 493838 32317 63972450
Sedation complication 36.12 10.40 17 493948 10337 63994430
Obesity 35.80 10.40 275 493690 20287 63984480
Balanoposthitis 35.51 10.40 37 493928 767 64004000
Granuloma skin 35.30 10.40 3 493962 6071 63998696
Acute myeloid leukaemia 35.25 10.40 101 493864 27362 63977405
Drug reaction with eosinophilia and systemic symptoms 34.96 10.40 257 493708 53960 63950807
Drug tolerance decreased 34.46 10.40 6 493959 6992 63997775
Diabetic foot 34.29 10.40 73 493892 2932 64001835
Angina pectoris 34.25 10.40 510 493455 44571 63960196
Pollakiuria 34.24 10.40 381 493584 31149 63973618
Body temperature decreased 34.20 10.40 326 493639 25602 63979165
Dyslipidaemia 34.20 10.40 151 493814 9091 63995676
Immunosuppressant drug level increased 34.09 10.40 7 493958 7252 63997515
Product substitution issue 34.01 10.40 244 493721 17617 63987150
Nephrogenic systemic fibrosis 33.99 10.40 3 493962 5889 63998878
Depression 33.93 10.40 1107 492858 182184 63822583
Hypophagia 33.74 10.40 457 493508 39130 63965637
Sedation 33.70 10.40 183 493782 41279 63963488
Urine ketone body 33.67 10.40 20 493945 172 64004595
Multiple-drug resistance 33.31 10.40 5 493960 6497 63998270
Intestinal perforation 33.19 10.40 41 493924 15272 63989495
Cytomegalovirus infection reactivation 33.02 10.40 3 493962 5753 63999014
Hypervolaemia 32.79 10.40 166 493799 38119 63966648
Disability 32.77 10.40 27 493938 12145 63992622
Neoplasm progression 32.64 10.40 182 493783 40782 63963985
Oedematous pancreatitis 32.48 10.40 37 493928 851 64003916
Lower respiratory tract infection 32.45 10.40 519 493446 94095 63910672
Electrocardiogram T wave peaked 32.32 10.40 36 493929 807 64003960
Basal cell carcinoma 32.30 10.40 124 493841 30714 63974053
Panniculitis 31.88 10.40 14 493951 8865 63995902
No adverse event 31.78 10.40 112 493853 28449 63976318
Unevaluable event 31.75 10.40 241 493724 50248 63954519
Anxiety 31.59 10.40 1250 492715 201399 63803368
Pneumothorax 31.45 10.40 89 493876 24209 63980558
Immunodeficiency 31.09 10.40 47 493918 16077 63988690
Asthenia 31.05 10.40 3738 490227 424306 63580461
Dry eye 30.83 10.40 116 493849 28903 63975864
Blindness transient 30.76 10.40 85 493880 4037 64000730
Complications of transplanted kidney 30.74 10.40 3 493962 5432 63999335
Peritonitis 30.69 10.40 94 493871 24929 63979838
Erythema 30.67 10.40 1147 492818 185923 63818844
Ulcer 30.66 10.40 83 493882 22907 63981860
Bradyarrhythmia 30.57 10.40 80 493885 3678 64001089
Haematuria 30.51 10.40 641 493324 59830 63944937
Blood triglycerides increased 30.48 10.40 248 493717 18618 63986149
Medication error 30.42 10.40 545 493420 49421 63955346
Obstructive pancreatitis 30.16 10.40 31 493934 632 64004135
5-hydroxyindolacetic acid in urine increased 30.04 10.40 20 493945 214 64004553
Blood mercury abnormal 29.78 10.40 19 493946 188 64004579
Hypoxia 29.74 10.40 485 493480 87664 63917103
Device related infection 29.65 10.40 127 493838 30499 63974268
Oxygen saturation decreased 29.49 10.40 611 493354 106565 63898202
Glomerular filtration rate abnormal 29.45 10.40 42 493923 1217 64003550
Plasma cell myeloma 29.42 10.40 219 493746 45856 63958911
Coma 29.39 10.40 879 493086 86736 63918031
Pseudomonas infection 29.13 10.40 58 493907 17825 63986942
Blood parathyroid hormone decreased 29.11 10.40 10 493955 7356 63997411
Bursitis 29.08 10.40 77 493888 21408 63983359
Status epilepticus 29.05 10.40 78 493887 21585 63983182
Complication associated with device 29.04 10.40 44 493921 15036 63989731
Aggression 28.92 10.40 221 493744 46011 63958756
Fibromyalgia 28.88 10.40 158 493807 35573 63969194
Myelodysplastic syndrome 28.81 10.40 111 493854 27468 63977299
Allergic reaction to excipient 28.70 10.40 20 493945 232 64004535
Pulmonary haemorrhage 28.52 10.40 35 493930 13074 63991693
Wrong patient received product 28.50 10.40 78 493887 3684 64001083
Lumbosacral radiculoplexus neuropathy 28.46 10.40 13 493952 60 64004707
Serotonin syndrome 28.40 10.40 180 493785 39102 63965665
Insomnia 28.36 10.40 1232 492733 196604 63808163
Haemoptysis 28.14 10.40 240 493725 48808 63955959
Atrioventricular block complete 28.06 10.40 198 493767 14220 63990547
Myopathy 27.80 10.40 231 493734 17449 63987318
Chills 27.59 10.40 820 493145 136444 63868323
Hypoparathyroidism 27.55 10.40 34 493931 853 64003914
Decreased appetite 27.55 10.40 2507 491458 278782 63725985
Cerebral venous thrombosis 27.51 10.40 59 493906 2382 64002385
Urinary tract discomfort 27.44 10.40 22 493943 320 64004447
Hypocalcaemia 27.42 10.40 461 493504 41292 63963475
Product monitoring error 27.35 10.40 98 493867 5356 63999411
Disease recurrence 27.34 10.40 136 493829 31374 63973393
Leukocytosis 27.14 10.40 423 493542 37317 63967450
Enterococcal infection 27.14 10.40 40 493925 13826 63990941
Generalised tonic-clonic seizure 27.12 10.40 186 493779 39671 63965096
Hyperventilation 27.03 10.40 114 493851 6726 63998041
Ascites 27.02 10.40 324 493641 61677 63943090
Tinnitus 27.01 10.40 152 493813 33981 63970786
Blood insulin decreased 26.97 10.40 9 493956 13 64004754
Device use error 26.97 10.40 8 493957 6463 63998304
Blood pressure fluctuation 26.64 10.40 261 493704 51610 63953157
Constipation 26.64 10.40 1460 492505 227877 63776890
Cholestatic liver injury 26.61 10.40 75 493890 3604 64001163
Coma scale abnormal 26.52 10.40 124 493841 7650 63997117
Haemofiltration 26.51 10.40 12 493953 54 64004713
Acquired phimosis 26.32 10.40 11 493954 39 64004728
Body mass index increased 26.23 10.40 45 493920 1534 64003233
Osteoarthritis 26.09 10.40 335 493630 63001 63941766
Blood calcium decreased 25.96 10.40 104 493861 25450 63979317
Chronic sinusitis 25.82 10.40 8 493957 6284 63998483
Hypoaesthesia 25.77 10.40 840 493125 138268 63866499
Metabolic syndrome 25.60 10.40 56 493909 2292 64002475
Tumour lysis syndrome 25.31 10.40 71 493894 19369 63985398
Respiratory syncytial virus infection 25.25 10.40 12 493953 7256 63997511
Anaphylactic reaction 25.12 10.40 372 493593 68292 63936475
Device issue 25.07 10.40 89 493876 22559 63982208
Respiratory arrest 25.00 10.40 272 493693 52713 63952054
Type V hyperlipidaemia 24.94 10.40 33 493932 889 64003878
Foot deformity 24.81 10.40 56 493909 16448 63988319
Pain in extremity 24.80 10.40 1991 491974 301094 63703673
Insulin-like growth factor increased 24.75 10.40 45 493920 1607 64003160
Cardiogenic shock 24.69 10.40 367 493598 32060 63972707
Cytomegalovirus chorioretinitis 24.66 10.40 4 493961 4908 63999859
Tongue oedema 24.59 10.40 101 493864 5889 63998878
Conjunctivitis 24.58 10.40 77 493888 20277 63984490
Apolipoprotein A-I decreased 24.54 10.40 9 493956 20 64004747
Epistaxis 24.53 10.40 568 493397 97563 63907204
Lung disorder 24.29 10.40 323 493642 60377 63944390
Ileus 24.27 10.40 92 493873 22874 63981893
Burkholderia pseudomallei infection 24.02 10.40 10 493955 35 64004732
Tubulointerstitial nephritis 24.00 10.40 351 493614 30558 63974209
Blood pressure systolic increased 23.91 10.40 521 493444 48932 63955835
Erythromelalgia 23.89 10.40 16 493949 173 64004594
Hyponatraemia 23.78 10.40 1376 492589 146963 63857804
Musculoskeletal disorder 23.61 10.40 65 493900 17841 63986926
Brain oedema 23.61 10.40 88 493877 21987 63982780
Liver disorder 23.55 10.40 278 493687 53073 63951694
Body temperature increased 23.54 10.40 174 493791 36492 63968275
Bacteraemia 23.43 10.40 116 493849 26795 63977972
Graft versus host disease in skin 23.43 10.40 6 493959 5341 63999426
Injection site warmth 23.39 10.40 42 493923 13420 63991347
Bone density decreased 23.35 10.40 25 493940 9927 63994840
Pancreatic pseudocyst 23.27 10.40 38 493927 1243 64003524
Antipsychotic drug level increased 23.21 10.40 89 493876 5026 63999741
Macular oedema 23.18 10.40 86 493879 4781 63999986
Abnormal loss of weight 23.05 10.40 115 493850 7285 63997482
Device dislocation 22.93 10.40 84 493881 21094 63983673
Infusion site erythema 22.90 10.40 12 493953 6861 63997906
Femur fracture 22.88 10.40 160 493805 33975 63970792
Polymyalgia rheumatica 22.86 10.40 67 493898 3292 64001475
Cytopenia 22.85 10.40 53 493912 15418 63989349
Drug ineffective for unapproved indication 22.85 10.40 142 493823 30991 63973776
Colitis 22.83 10.40 314 493651 58360 63946407
Retroperitoneal fibrosis 22.82 10.40 25 493940 550 64004217
Joint range of motion decreased 22.78 10.40 74 493891 19269 63985498
Coordination abnormal 22.73 10.40 194 493771 14770 63989997
Vitamin B1 deficiency 22.64 10.40 25 493940 555 64004212
Actinic elastosis 22.63 10.40 10 493955 42 64004725
Pulseless electrical activity 22.53 10.40 171 493794 12568 63992199
Resuscitation 22.46 10.40 49 493916 2002 64002765
Anion gap abnormal 22.34 10.40 24 493941 516 64004251
Atrial fibrillation 22.30 10.40 1559 492406 169530 63835237
Central obesity 22.27 10.40 40 493925 1415 64003352
Swollen tongue 22.25 10.40 384 493581 34570 63970197
Enterocolitis 22.25 10.40 36 493929 11982 63992785
Haemorrhage 22.23 10.40 451 493514 78900 63925867
Adrenal adenoma 22.14 10.40 33 493932 996 64003771
Cytomegalovirus test positive 22.11 10.40 6 493959 5138 63999629
Pneumonia aspiration 22.07 10.40 320 493645 58951 63945816
Temperature perception test abnormal 22.05 10.40 8 493957 17 64004750
Neuropathy vitamin B12 deficiency 21.95 10.40 9 493956 30 64004737
Balanitis candida 21.87 10.40 13 493952 112 64004655
Non-alcoholic steatohepatitis 21.79 10.40 47 493918 1905 64002862
Cardiotoxicity 21.76 10.40 28 493937 10246 63994521
Joint effusion 21.69 10.40 44 493921 13429 63991338
PO2 increased 21.55 10.40 40 493925 1452 64003315
Febrile bone marrow aplasia 21.52 10.40 33 493932 11222 63993545
Back pain 21.45 10.40 1637 492328 248534 63756233
Vitreous haemorrhage 21.44 10.40 62 493903 3023 64001744
Sepsis 21.39 10.40 1497 492468 228844 63775923
Pernicious anaemia 21.31 10.40 24 493941 545 64004222
Malnutrition 21.28 10.40 75 493890 19050 63985717
Injection site swelling 21.27 10.40 208 493757 41145 63963622
Nipple inflammation 21.26 10.40 10 493955 50 64004717
Dysentery 21.22 10.40 30 493935 862 64003905
Substance abuse 21.08 10.40 24 493941 9268 63995499
Hepatojugular reflux 21.06 10.40 23 493942 504 64004263
Liver palpable 21.03 10.40 19 493946 328 64004439
Urine output increased 20.99 10.40 45 493920 1816 64002951
Erectile dysfunction 20.95 10.40 167 493798 12460 63992307
Neuroendocrine tumour 20.93 10.40 34 493931 1107 64003660
Aplasia pure red cell 20.89 10.40 14 493951 7000 63997767
Grip strength decreased 20.89 10.40 36 493929 11688 63993079
Hyperinsulinaemic hypoglycaemia 20.86 10.40 13 493952 123 64004644
Injection site bruising 20.85 10.40 178 493787 36195 63968572
Blood chloride decreased 20.85 10.40 112 493853 7304 63997463
Anovulatory cycle 20.82 10.40 12 493953 97 64004670
Haemoglobin decreased 20.62 10.40 1253 492712 193810 63810957
Neoplasm malignant 20.60 10.40 108 493857 24580 63980187
Hemiparesis 20.58 10.40 332 493633 29495 63975272
Suicidal ideation 20.54 10.40 372 493593 66170 63938597
Psoriatic arthropathy 20.49 10.40 222 493743 43059 63961708
Product administered to patient of inappropriate age 20.48 10.40 5 493960 4596 64000171
Large intestine perforation 20.42 10.40 41 493924 12563 63992204
Ischaemic cardiomyopathy 20.42 10.40 105 493860 6733 63998034
Hallucination 20.30 10.40 414 493551 72374 63932393
Adverse event 20.15 10.40 199 493766 39290 63965477
Joint stiffness 20.14 10.40 143 493822 30261 63974506
Postmenopausal haemorrhage 20.13 10.40 38 493927 1397 64003370
Pulmonary arterial hypertension 20.05 10.40 113 493852 25254 63979513
IIIrd nerve paresis 20.04 10.40 14 493951 163 64004604
Blood phosphorus increased 19.99 10.40 83 493882 4863 63999904
Neuropathic arthropathy 19.96 10.40 18 493947 310 64004457
Mydriasis 19.88 10.40 56 493909 15256 63989511
Hypogammaglobulinaemia 19.88 10.40 30 493935 10269 63994498
Starvation ketoacidosis 19.84 10.40 12 493953 107 64004660
Necrotising myositis 19.71 10.40 29 493936 865 64003902
Upper respiratory tract infection 19.71 10.40 416 493549 72369 63932398
Throat irritation 19.70 10.40 158 493807 32553 63972214
Nipple disorder 19.69 10.40 14 493951 168 64004599
Fixed eruption 19.69 10.40 48 493917 2111 64002656
Alveolar osteitis 19.69 10.40 20 493945 402 64004365
Haematocrit decreased 19.68 10.40 297 493668 54358 63950409
Diabetic ulcer 19.66 10.40 16 493949 238 64004529
Multiple organ dysfunction syndrome 19.51 10.40 957 493008 100456 63904311
Birt-Hogg-Dube syndrome 19.40 10.40 5 493960 0 64004767
Cold sweat 19.33 10.40 202 493763 16253 63988514
Drug eruption 19.33 10.40 180 493785 35956 63968811
Pelvic fracture 19.22 10.40 32 493933 10531 63994236
Pulmonary valve disease 19.17 10.40 16 493949 247 64004520
Diabetes mellitus management 19.17 10.40 6 493959 6 64004761
Pancreatitis haemorrhagic 19.10 10.40 23 493942 562 64004205
Food aversion 18.91 10.40 25 493940 673 64004094
Drug withdrawal syndrome 18.91 10.40 151 493814 31140 63973627
Hyperinsulinaemia 18.89 10.40 14 493951 180 64004587
Ischaemic stroke 18.86 10.40 320 493645 28715 63976052
Dysarthria 18.85 10.40 592 493373 58814 63945953
Poisoning 18.82 10.40 253 493712 21626 63983141
Deep vein thrombosis 18.80 10.40 638 493327 104544 63900223
Thrombosis 18.76 10.40 405 493560 70237 63934530
Hyperoxaluria 18.75 10.40 16 493949 255 64004512
Aplastic anaemia 18.75 10.40 50 493915 13870 63990897
Malabsorption 18.68 10.40 75 493890 4328 64000439
Cystitis haemorrhagic 18.65 10.40 20 493945 7936 63996831
Intentional self-injury 18.56 10.40 138 493827 28906 63975861
Colitis ulcerative 18.52 10.40 102 493863 22926 63981841
Viral infection 18.49 10.40 182 493783 35958 63968809
Bundle branch block left 18.49 10.40 136 493829 9898 63994869
Peripheral sensory neuropathy 18.45 10.40 37 493928 11341 63993426
Renal oncocytoma 18.42 10.40 10 493955 71 64004696
Albumin urine present 18.41 10.40 24 493941 637 64004130
Diabetic hyperosmolar coma 18.41 10.40 25 493940 691 64004076
Venoocclusive disease 18.39 10.40 4 493961 3981 64000786
Pulmonary tuberculosis 18.37 10.40 17 493948 7227 63997540
Dizziness 18.36 10.40 3647 490318 426516 63578251
Incorrect route of product administration 18.30 10.40 104 493861 23194 63981573
Blood cholesterol 18.28 10.40 18 493947 348 64004419
Staphylococcal bacteraemia 18.27 10.40 32 493933 10323 63994444
Glomerular filtration rate increased 18.20 10.40 21 493944 490 64004277
Akathisia 18.18 10.40 38 493927 11472 63993295
Vitamin B1 decreased 18.15 10.40 17 493948 308 64004459
Exercise tolerance decreased 18.11 10.40 111 493854 7599 63997168
Left ventricular dysfunction 18.02 10.40 204 493761 16750 63988017
Cytomegalovirus colitis 18.01 10.40 4 493961 3924 64000843
Bone pain 18.00 10.40 256 493709 47316 63957451
Anaemia macrocytic 17.93 10.40 74 493891 4324 64000443
Hepatic vein dilatation 17.90 10.40 15 493950 233 64004534
Lymphadenopathy 17.75 10.40 251 493714 46435 63958332
Red blood cell count decreased 17.75 10.40 262 493703 48124 63956643
Atelectasis 17.69 10.40 129 493836 27137 63977630
Pneumonitis 17.69 10.40 275 493690 50090 63954677
Pneumatosis intestinalis 17.61 10.40 9 493956 5220 63999547
Overweight 17.53 10.40 61 493904 3285 64001482
Pulmonary toxicity 17.45 10.40 24 493941 8537 63996230
Product quality issue 17.42 10.40 323 493642 29476 63975291
Blood creatine phosphokinase increased 17.40 10.40 579 493386 57979 63946788
Rhinovirus infection 17.40 10.40 13 493952 6143 63998624
Hypertensive crisis 17.37 10.40 215 493750 18033 63986734
Disseminated intravascular coagulation 17.36 10.40 161 493804 32187 63972580
Prothrombin consumption time prolonged 17.33 10.40 8 493957 38 64004729
Aphasia 17.31 10.40 423 493542 40483 63964284
Labelled drug-disease interaction medication error 17.26 10.40 16 493949 286 64004481
Dysuria 17.23 10.40 433 493532 41624 63963143
Urosepsis 17.19 10.40 251 493714 21843 63982924
Intercapillary glomerulosclerosis 17.17 10.40 9 493956 59 64004708
Urine albumin/creatinine ratio increased 17.17 10.40 17 493948 331 64004436
Neutropenic sepsis 17.15 10.40 106 493859 23166 63981601
Brain stem infarction 17.13 10.40 41 493924 1782 64002985
Albuminuria 17.12 10.40 23 493942 629 64004138
Wrong technique in product usage process 17.11 10.40 373 493592 64601 63940166
Scrotal cyst 17.07 10.40 5 493960 3 64004764
Cutaneous vasculitis 17.02 10.40 96 493869 6377 63998390
Methaemoglobinaemia 17.02 10.40 6 493959 4342 64000425
Cerebellar ischaemia 16.95 10.40 12 493953 143 64004624
Leukoencephalopathy 16.91 10.40 17 493948 6950 63997817
Pleural fibrosis 16.89 10.40 5 493960 4045 64000722
Blood growth hormone abnormal 16.85 10.40 8 493957 41 64004726
Mitochondrial enzyme deficiency 16.71 10.40 7 493958 25 64004742
CD30 expression 16.70 10.40 8 493957 42 64004725
Drug half-life increased 16.66 10.40 11 493954 116 64004651
Renal abscess 16.60 10.40 27 493938 880 64003887
Sensory loss 16.60 10.40 134 493831 10035 63994732
Microcytic anaemia 16.58 10.40 75 493890 4563 64000204
Decreased bronchial secretion 16.57 10.40 9 493956 64 64004703
Product appearance confusion 16.55 10.40 8 493957 43 64004724
Tooth disorder 16.53 10.40 102 493863 22300 63982467
Purpura 16.40 10.40 72 493893 17174 63987593
Azotaemia 16.38 10.40 106 493859 7396 63997371
Pulmonary alveolar haemorrhage 16.37 10.40 31 493934 9707 63995060
Fibrillary glomerulonephritis 16.26 10.40 8 493957 45 64004722
Diabetic gangrene 16.08 10.40 12 493953 156 64004611
Intestinal obstruction 16.05 10.40 189 493776 36097 63968670
Therapy partial responder 16.04 10.40 34 493931 10214 63994553
Hepatic neoplasm 16.04 10.40 56 493909 3021 64001746
Transfusion 15.99 10.40 77 493888 17917 63986850
Foreign body aspiration 15.96 10.40 15 493950 273 64004494
Pneumonia viral 15.87 10.40 22 493943 7800 63996967
Neuropathy, ataxia, retinitis pigmentosa syndrome 15.84 10.40 8 493957 48 64004719
Phimosis 15.83 10.40 18 493947 413 64004354
Liver function test increased 15.83 10.40 156 493809 30814 63973953
Encephalitis toxic 15.83 10.40 15 493950 276 64004491
Tongue disorder 15.82 10.40 44 493921 12036 63992731
Prostatitis 15.76 10.40 62 493903 3544 64001223
Drug specific antibody present 15.74 10.40 10 493955 5144 63999623
Bacterial infection 15.73 10.40 119 493846 24831 63979936
Diffuse large B-cell lymphoma 15.70 10.40 35 493930 10326 63994441
Unresponsive to stimuli 15.68 10.40 501 493464 49892 63954875
Cardiovascular insufficiency 15.67 10.40 50 493915 2574 64002193
Therapeutic drug monitoring analysis not performed 15.67 10.40 31 493934 1181 64003586
Palmar-plantar erythrodysaesthesia syndrome 15.65 10.40 143 493822 28676 63976091
Herpes simplex 15.64 10.40 36 493929 10500 63994267
Pancreatic neuroendocrine tumour 15.63 10.40 19 493946 469 64004298
Hypoglycaemic seizure 15.63 10.40 24 493941 744 64004023
Drug use disorder 15.60 10.40 14 493951 6040 63998727
Blood lactate dehydrogenase increased 15.53 10.40 170 493795 32908 63971859
Labelled drug-disease interaction issue 15.52 10.40 4 493961 0 64004767
Atrioventricular node dysfunction 15.52 10.40 4 493961 0 64004767
Angina unstable 15.49 10.40 184 493781 15283 63989484
Diabetic complication 15.48 10.40 30 493935 1125 64003642
Low density lipoprotein decreased 15.46 10.40 29 493936 1061 64003706
Diabetic vascular disorder 15.44 10.40 8 493957 51 64004716
Injection site mass 15.39 10.40 201 493764 17069 63987698
Mechanical ventilation complication 15.38 10.40 7 493958 32 64004735
Necrotising fasciitis 15.36 10.40 81 493884 5245 63999522
Haemorrhoids 15.36 10.40 114 493851 23887 63980880
Pneumonia cytomegaloviral 15.33 10.40 7 493958 4332 64000435
Synovial cyst 15.31 10.40 22 493943 7685 63997082
Granuloma 15.23 10.40 17 493948 6624 63998143
Congenital hydrocephalus 15.21 10.40 7 493958 33 64004734
Hypoaesthesia eye 15.19 10.40 9 493956 77 64004690
Multiple sclerosis 15.17 10.40 84 493881 18857 63985910
Pericardial disease 15.14 10.40 19 493946 485 64004282
Insulin C-peptide increased 15.10 10.40 10 493955 106 64004661
Vascular device infection 15.09 10.40 15 493950 6165 63998602
Spinal compression fracture 15.09 10.40 60 493905 14715 63990052
Pancreatic mass 15.08 10.40 33 493932 1351 64003416
Medullary thyroid cancer 15.07 10.40 11 493954 138 64004629
Duodenal ulcer 15.03 10.40 173 493792 14262 63990505
Motor dysfunction 15.00 10.40 143 493822 11230 63993537
Bronchitis 14.99 10.40 680 493285 108063 63896704
Virologic failure 14.98 10.40 4 493961 3462 64001305
Blood growth hormone increased 14.92 10.40 21 493944 601 64004166
Catheter site infection 14.87 10.40 13 493952 5680 63999087
Genital swelling 14.86 10.40 15 493950 299 64004468
Low density lipoprotein abnormal 14.86 10.40 15 493950 299 64004468
Creatinine renal clearance 14.86 10.40 6 493959 19 64004748
Intracranial pressure increased 14.85 10.40 19 493946 6970 63997797
Fear of injection 14.85 10.40 14 493951 5898 63998869
Septic shock 14.80 10.40 658 493307 104779 63899988
Blindness 14.78 10.40 244 493721 21775 63982992
Parainfluenzae virus infection 14.77 10.40 9 493956 4734 64000033
Lupus-like syndrome 14.76 10.40 28 493937 8763 63996004
Skin necrosis 14.76 10.40 58 493907 14271 63990496
Drug level below therapeutic 14.75 10.40 21 493944 7363 63997404
Bone disorder 14.73 10.40 72 493893 16687 63988080
Hyperhidrosis 14.69 10.40 1129 492836 123791 63880976
Oesophagitis 14.69 10.40 101 493864 21529 63983238
Nodular rash 14.63 10.40 15 493950 305 64004462
Ventricular enlargement 14.59 10.40 19 493946 504 64004263
Expired product administered 14.58 10.40 87 493878 5900 63998867
Jaundice hepatocellular 14.57 10.40 10 493955 113 64004654
Musculoskeletal pain 14.55 10.40 493 493472 80801 63923966
Herbal interaction 14.46 10.40 17 493948 405 64004362
Cholecystitis chronic 14.42 10.40 121 493844 9166 63995601
Paraesthesia 14.40 10.40 863 493102 133659 63871108
Bronchostenosis 14.30 10.40 20 493945 569 64004198
Device malfunction 14.23 10.40 78 493887 17555 63987212
Skin turgor decreased 14.23 10.40 21 493944 628 64004139
Peripheral arterial occlusive disease 14.21 10.40 97 493868 6890 63997877
Hyperkinetic heart syndrome 14.21 10.40 10 493955 118 64004649
Dyskinesia 14.20 10.40 214 493751 39174 63965593
Atrioventricular block first degree 14.18 10.40 135 493830 10599 63994168
Varicella zoster virus infection 14.17 10.40 6 493959 3882 64000885
Cutaneous T-cell dyscrasia 14.16 10.40 8 493957 62 64004705
Helicobacter gastritis 14.14 10.40 43 493922 2157 64002610
Pyelonephritis acute 14.07 10.40 77 493888 5057 63999710
Coma uraemic 13.99 10.40 7 493958 41 64004726
Wrong dose 13.99 10.40 30 493935 1211 64003556
Bundle branch block right 13.98 10.40 130 493835 10139 63994628
Clostridium test positive 13.98 10.40 7 493958 4108 64000659
Neuropathic ulcer 13.95 10.40 8 493957 64 64004703
Hepatic enzyme decreased 13.94 10.40 9 493956 91 64004676
Appendicitis 13.93 10.40 55 493910 13514 63991253
Respiratory tract infection 13.91 10.40 202 493763 37205 63967562
Wheezing 13.88 10.40 491 493474 80088 63924679
Orbital oedema 13.88 10.40 14 493951 279 64004488
Arrhythmia 13.87 10.40 516 493449 52428 63952339
Electrolyte imbalance 13.86 10.40 271 493694 24972 63979795
Scleroderma 13.84 10.40 10 493955 4808 63999959
Shock hypoglycaemic 13.82 10.40 13 493952 237 64004530
Pancreatitis necrotising 13.81 10.40 55 493910 3162 64001605
Mycobacterial infection 13.79 10.40 3 493962 2985 64001782
Prostatomegaly 13.77 10.40 52 493913 2915 64001852
Rash erythematous 13.74 10.40 276 493689 48357 63956410
Paradoxical drug reaction 13.67 10.40 16 493949 6104 63998663
Aplasia 13.67 10.40 20 493945 6933 63997834
Cornea verticillata 13.62 10.40 9 493956 95 64004672
Cerebral haematoma 13.59 10.40 98 493867 7087 63997680
Muscular weakness 13.54 10.40 1142 492823 126196 63878571
Diabetic coma 13.51 10.40 28 493937 1103 64003664
Tunnel vision 13.48 10.40 27 493938 1038 64003729
Miosis 13.47 10.40 54 493911 13212 63991555
Genitourinary symptom 13.47 10.40 13 493952 245 64004522
Treatment noncompliance 13.45 10.40 432 493533 43050 63961717
Skin papilloma 13.45 10.40 12 493953 5191 63999576
Electroencephalogram abnormal 13.45 10.40 12 493953 5191 63999576
Pneumonia fungal 13.44 10.40 30 493935 8847 63995920
Hyponatraemic encephalopathy 13.44 10.40 14 493951 290 64004477
Genital rash 13.44 10.40 24 493941 845 64003922
Extrapyramidal disorder 13.42 10.40 91 493874 19461 63985306
Clonus 13.41 10.40 16 493949 6051 63998716
Loss of consciousness 13.41 10.40 1315 492650 147050 63857717
Pharyngitis streptococcal 13.37 10.40 29 493936 8639 63996128
Device difficult to use 13.35 10.40 35 493930 9763 63995004
Diabetic cheiroarthropathy 13.30 10.40 4 493961 3 64004764
Red blood cells urine positive 13.26 10.40 9 493956 4469 64000298
Bladder neoplasm 13.23 10.40 33 493932 1473 64003294
Bacterial sepsis 13.19 10.40 23 493942 7434 63997333
Gastrointestinal disorder 13.18 10.40 557 493408 89152 63915615
Infusion site extravasation 13.11 10.40 20 493945 6817 63997950
Temperature regulation disorder 13.10 10.40 8 493957 4203 64000564
Genital tract inflammation 13.08 10.40 6 493959 28 64004739
Retinal artery thrombosis 13.01 10.40 9 493956 103 64004664
Neck pain 13.01 10.40 365 493600 61168 63943599
Coeliac disease 12.99 10.40 23 493942 7389 63997378
Pneumonia bacterial 12.98 10.40 65 493900 14970 63989797
Osteopenia 12.96 10.40 68 493897 15472 63989295
Pruritus genital 12.86 10.40 26 493939 1006 64003761
Urethral intrinsic sphincter deficiency 12.83 10.40 5 493960 14 64004753
Bladder sphincter atony 12.80 10.40 9 493956 106 64004661
Lymphoma 12.78 10.40 59 493906 13882 63990885
Venous aneurysm 12.78 10.40 4 493961 4 64004763
Carbohydrate metabolism disorder 12.76 10.40 6 493959 30 64004737
Blood lactic acid abnormal 12.76 10.40 6 493959 30 64004737
Cardiopulmonary failure 12.75 10.40 86 493879 6084 63998683
Catheter site erythema 12.75 10.40 11 493954 4838 63999929
Post-traumatic amnestic disorder 12.75 10.40 7 493958 51 64004716
Autoimmune pancreatitis 12.71 10.40 19 493946 575 64004192
Crush syndrome 12.71 10.40 11 493954 179 64004588
Transient ischaemic attack 12.65 10.40 435 493530 43747 63961020
Optic neuritis 12.65 10.40 27 493938 8089 63996678
Rales 12.64 10.40 175 493790 15054 63989713
Lip swelling 12.63 10.40 327 493638 31580 63973187
Endometriosis male 12.58 10.40 5 493960 15 64004752
Bladder pain 12.58 10.40 36 493929 1745 64003022
Pruritus 12.58 10.40 2152 491813 310248 63694519
Plasmapheresis 12.57 10.40 19 493946 581 64004186
Clear cell renal cell carcinoma 12.54 10.40 41 493924 2138 64002629
Carcinoid tumour of the stomach 12.51 10.40 11 493954 183 64004584
Hypoperfusion 12.49 10.40 43 493922 2303 64002464
Blood cholesterol increased 12.45 10.40 290 493675 49776 63954991
Base excess 12.38 10.40 8 493957 81 64004686
pH urine decreased 12.35 10.40 5 493960 16 64004751
Glycosylated haemoglobin 12.35 10.40 5 493960 16 64004751
Alcoholic ketoacidosis 12.35 10.40 5 493960 16 64004751
Intervertebral disc degeneration 12.34 10.40 55 493910 13065 63991702
Ear infection 12.34 10.40 117 493848 23287 63981480
Gingival oedema 12.31 10.40 7 493958 55 64004712
Food craving 12.29 10.40 31 493934 1393 64003374
Cortisol increased 12.27 10.40 16 493949 425 64004342
Hypochromic anaemia 12.26 10.40 43 493922 2325 64002442
Cryptococcosis 12.25 10.40 3 493962 2752 64002015
Myoclonus 12.23 10.40 128 493837 24990 63979777
Differential white blood cell count abnormal 12.22 10.40 36 493929 1774 64002993
Premature labour 12.17 10.40 25 493940 7595 63997172
Central venous catheterisation 12.16 10.40 3 493962 2738 64002029
Schizophrenia 12.15 10.40 135 493830 11033 63993734
Blood albumin decreased 12.14 10.40 103 493862 20970 63983797
Drug abuser 12.12 10.40 16 493949 5792 63998975
Bladder papilloma 12.12 10.40 5 493960 17 64004750
Cardiac failure chronic 12.08 10.40 114 493851 8927 63995840
Joint dislocation 12.07 10.40 46 493919 11419 63993348
Carcinoid tumour 12.07 10.40 16 493949 432 64004335
Hyperlipasaemia 12.06 10.40 25 493940 985 64003782
Adrenal cyst 12.06 10.40 8 493957 85 64004682
Fungaemia 12.04 10.40 7 493958 3778 64000989
Acute lymphocytic leukaemia recurrent 12.04 10.40 8 493957 4018 64000749
Lipids abnormal 12.01 10.40 17 493948 489 64004278
Small intestinal obstruction 11.94 10.40 119 493846 23454 63981313
Meningitis 11.93 10.40 29 493936 8300 63996467
Renal artery thrombosis 11.93 10.40 16 493949 437 64004330
Neutrophilia 11.92 10.40 90 493875 6604 63998163
Venous pressure jugular 11.91 10.40 5 493960 18 64004749
Anaphylactic shock 11.91 10.40 162 493803 30166 63974601
Mucosal dryness 11.85 10.40 50 493915 2951 64001816
Eructation 11.84 10.40 115 493850 9076 63995691
Pyelonephritis 11.84 10.40 192 493773 17074 63987693
Blood ketone body present 11.81 10.40 7 493958 60 64004707
Oxygen saturation immeasurable 11.74 10.40 6 493959 37 64004730
Cellulitis of male external genital organ 11.74 10.40 6 493959 37 64004730
Acanthosis 11.71 10.40 15 493950 391 64004376
Foetal death 11.71 10.40 17 493948 5913 63998854
Physical examination abnormal 11.66 10.40 12 493953 245 64004522
Oedema 11.66 10.40 580 493385 91355 63913412
Lichenification 11.65 10.40 20 493945 682 64004085
Cholangiocarcinoma 11.64 10.40 38 493927 1980 64002787
Transitional cell carcinoma urethra 11.64 10.40 3 493962 0 64004767
Malignant neoplasm of thymus 11.64 10.40 3 493962 0 64004767
Diabetic dyslipidaemia 11.64 10.40 3 493962 0 64004767
Babinski reflex test 11.64 10.40 3 493962 0 64004767
Pancreatic enzymes abnormal 11.64 10.40 3 493962 0 64004767
Diet failure 11.61 10.40 6 493959 38 64004729
Epileptic encephalopathy 11.60 10.40 15 493950 395 64004372
Low density lipoprotein increased 11.57 10.40 100 493865 7640 63997127
Aortic stenosis 11.57 10.40 86 493879 6279 63998488
Skin induration 11.57 10.40 9 493956 4166 64000601
Drug-disease interaction 11.55 10.40 21 493944 750 64004017
Skin disorder 11.55 10.40 146 493819 27534 63977233
Ankylosing spondylitis 11.53 10.40 29 493936 8205 63996562
Deformity 11.53 10.40 19 493946 6278 63998489
Food allergy 11.51 10.40 27 493938 7824 63996943
Blood glucose normal 11.50 10.40 5 493960 20 64004747
Thyroid cancer recurrent 11.50 10.40 5 493960 20 64004747
Product solubility abnormal 11.50 10.40 22 493943 817 64003950
Peripheral vascular disorder 11.49 10.40 95 493870 7166 63997601
Arthritis bacterial 11.46 10.40 27 493938 7812 63996955
Eyelid bleeding 11.43 10.40 7 493958 64 64004703
Oral candidiasis 11.42 10.40 118 493847 23094 63981673
Intestinal ischaemia 11.40 10.40 137 493828 11412 63993355
Coronary artery bypass 11.40 10.40 80 493885 5735 63999032
Catheter site haemorrhage 11.38 10.40 11 493954 4580 64000187
Red cell distribution width abnormal 11.37 10.40 11 493954 208 64004559
Body mass index abnormal 11.37 10.40 11 493954 208 64004559
Malignant mediastinal neoplasm 11.31 10.40 17 493948 517 64004250
Blood bicarbonate abnormal 11.28 10.40 9 493956 130 64004637
Pancreatic enzymes increased 11.27 10.40 27 493938 1174 64003593
Endoscopy upper gastrointestinal tract 11.25 10.40 8 493957 96 64004671
Genital infection female 11.25 10.40 7 493958 66 64004701
Acid base balance abnormal 11.24 10.40 13 493952 304 64004463
Gamma-glutamyltransferase abnormal 11.23 10.40 16 493949 463 64004304
Stenosis 11.22 10.40 35 493930 1780 64002987
Leukaemia recurrent 11.20 10.40 3 493962 2591 64002176
Respiratory depression 11.19 10.40 120 493845 23323 63981444
Accidental underdose 11.17 10.40 19 493946 643 64004124
Acute hepatic failure 11.17 10.40 137 493828 25975 63978792
Product administration error 11.14 10.40 284 493681 27359 63977408
Penile infection 11.13 10.40 5 493960 22 64004745
Hyperphagia 11.11 10.40 40 493925 2191 64002576
Anaesthetic complication 11.10 10.40 3 493962 2576 64002191
Blood sodium decreased 11.05 10.40 300 493665 29182 63975585
Hypertensive angiopathy 11.05 10.40 8 493957 99 64004668
Right ventricular failure 11.04 10.40 108 493857 21363 63983404
Gingival hypertrophy 11.03 10.40 46 493919 2701 64002066
Catheter management 10.97 10.40 6 493959 3349 64001418
Psychogenic tremor 10.96 10.40 5 493960 23 64004744
Autoimmune myositis 10.96 10.40 10 493955 175 64004592
Chronic pigmented purpura 10.96 10.40 10 493955 175 64004592
Cough 10.96 10.40 2093 491872 300055 63704712
Drug level decreased 10.95 10.40 48 493917 11455 63993312
Adrenomegaly 10.93 10.40 14 493951 365 64004402
Bladder cancer recurrent 10.87 10.40 15 493950 421 64004346
Hepatosplenomegaly 10.87 10.40 15 493950 5328 63999439
Left atrial dilatation 10.85 10.40 46 493919 2720 64002047
Diabetic macroangiopathy 10.83 10.40 9 493956 138 64004629
Empty sella syndrome 10.83 10.40 7 493958 71 64004696
Prescription drug used without a prescription 10.80 10.40 44 493921 2556 64002211
Pancreatic failure 10.79 10.40 30 493935 1430 64003337
Clostridial infection 10.79 10.40 14 493951 5105 63999662
Peripheral artery haematoma 10.78 10.40 6 493959 45 64004722
Psychotic disorder 10.77 10.40 193 493772 34385 63970382
Infusion site pain 10.76 10.40 42 493923 10355 63994412
Duodenal ulcer haemorrhage 10.68 10.40 84 493881 6241 63998526
Upper respiratory tract inflammation 10.67 10.40 8 493957 3774 64000993
Skin lesion 10.62 10.40 206 493759 36276 63968491
Inferior vena cava dilatation 10.62 10.40 20 493945 734 64004033
Enterococcal bacteraemia 10.62 10.40 3 493962 2502 64002265
Cardiorenal syndrome 10.57 10.40 27 493938 1223 64003544
Emphysematous pyelonephritis 10.56 10.40 11 493954 228 64004539
Postoperative wound infection 10.54 10.40 42 493923 10294 63994473
Blood pressure inadequately controlled 10.51 10.40 74 493891 5310 63999457
Soft tissue disorder 10.51 10.40 6 493959 3270 64001497
Increased tendency to bruise 10.49 10.40 36 493929 9219 63995548
Lichen sclerosus 10.48 10.40 22 493943 875 64003892
Bladder transitional cell carcinoma stage III 10.47 10.40 5 493960 26 64004741
Embolism venous 10.45 10.40 7 493958 3500 64001267
Hypomania 10.41 10.40 17 493948 5637 63999130

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD26 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0002471 Biguanides
FDA EPC N0000175565 Biguanide
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Polycystic ovary syndrome off-label use 237055002 DOID:11612
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe Hypoxemia contraindication
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Autonomic Insufficiency contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
2.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
2.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;1GM SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;500MG SEGLUROMET MERCK SHARP DOHME N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
D00944 KEGG_DRUG
1115-70-4 SECONDARY_CAS_RN
4020898 VANDF
4023979 VANDF
C0025598 UMLSCUI
CHEBI:6801 CHEBI
MF8 PDB_CHEM_ID
CHEMBL1431 ChEMBL_ID
4091 PUBCHEM_CID
DB00331 DRUGBANK_ID
CHEMBL1703 ChEMBL_ID
D008687 MESH_DESCRIPTOR_UI
965 INN_ID
4779 IUPHAR_LIGAND_ID
9100L32L2N UNII
151827 RXNORM
41717 MMSL
5063 MMSL
592 MMSL
d03807 MMSL
003483 NDDF
004534 NDDF
109081006 SNOMEDCT_US
109083009 SNOMEDCT_US
372567009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2751 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2752 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2753 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6125 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6135 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6145 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6225 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6225 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6250 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6250 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6260 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6260 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6270 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6270 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6280 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6280 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6001 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 29 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6002 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 29 sections